Abstract: This review describes the nature and applications of ribosome inactivating proteins (RIPs) from Momordica charantia (bitter melon). RIPs from the plant kingdom have received much attention in biomedical research because they target conserved host protein synthesis machinery and show specificity towards human and animal cell targets. Recent studies aimed at unravelling the enzymatic activities of the M charantia RIPs provide a structural basis for their activities. It has been reported that RIPs are member of the single chain ribosome inactivating protein (SCRIP) family which act irreversibly on ribosome by removing adenine residue from eukaryotic ribosomal RNA. Various activities of RIPs include anti-tumor, broad anti-viral, ribonuclease and deoxyribonuclease. MAP30 (Momordica Anti-HIV Protein), -and -momorcharins inhibit HIV replication in acutely and chronically infected cells and thus are considered potential therapeutic agent in HIV infection and AIDS. Further, MAP30 improved the efficacy of anti-HIV therapy when used in combination with other anti-viral drugs. MAP30 holds therapeutic promise over other RIPs because not only it is active against infection and replication of both HSV and HIV but is non toxic to normal cells. Here we review the nature, action, structure function relationship and applications of RIPs from Momordica charantia and evaluate their potential for anticancer and anti-viral therapy.
INTRODUCTION
It has long been known that plants represent a natural source of chemicals that can be used for the treatment of diseases [1] . Natural products from plants have provided the pharmaceutical industry with one of its most important sources of 'lead' compounds and up to 40% of modern drugs are derived from natural sources, using either the natural substance or a synthetic derivative [2] . Many plants possess specific metabolic pathways to produce small molecules such as alkaloids and flavonoids, which have therapeutic potential as well [3] . Plants also synthesize a number of valuable proteins which are widely distributed among different plant genera and within a variety of different tissue. Such proteins have been linked to plant defense by antiviral, antifungal and insecticidal properties demonstrated in vitro and in transgenic plants [4] . One such example of proteins are 'ribosome inactivating proteins i.e. RIPs [5] .
RIPs are toxic N-glycosidases that depurinate the universally conserved -sarcin loop of large ribosomal ribonucleic acid (rRNA). This depurination irreversibly inactivates the ribosome, thereby blocking its further *Address correspondence to this author at the Centre for Biotechnology and Interdisciplinary Biology (BioDeakin), Institute for Technology Research and Innovation (ITRI), Deakin University, Geelong, Victoria 3217, Australia; Tel: +61-3-52272325; Fax: 61-3-52272170; E-mail: munish.puri@deakin.edu.au participation in protein synthesis [5, 6] . Later it became evident that RIPs are also capable of inactivating nonribosomal nucleic acid substrates [7] [8] [9] and hence can be considered polynucleotide:adenosine glycosidases [8] . In the last decade, RIPs have become a subject of wide range of investigations such as antiviral, anti-tumor, abortifacient, antimicrobial and immunomodulatory activities [10] . There are two forms of RIPs (type I and type II) that have been isolated from leaves, seeds and roots of a wide variety of plants. Type 1 RIPs are single chain that contains an RNA Nglycosidase activity domain. The molecular mass of the majority of type 1 RIPs is in the range 23-35 kDa. Type II RIPs consist of two chains linked by a disulfide bridge; one chain is similar to type I RIPs, and the other chain is a lectin that combines with cell-surface glycoproteins or glycolipids to facilitate transport of the whole protein into the cell. Consequently, type II RIPs, such as ricin from Ricinus communis (castor bean), often show extreme toxicity [4, 10] . However, type I RIPs is much more numerous than their toxic relatives [9] . Besides the classical types of RIPs, a 60 kDa RIP (called JIP60) has been identified in barley (Hordeum vulgare) that consists of an amino-terminal domain resembling type I RIPs linked to an unrelated carboxylterminal domain with unknown function. JIP 60 has been called a type III RIP [11] .
Momordica charantia (MC) is a plant that has been frequently used worldwide as a folk medicine [12] . MC, commonly known as bitter gourd or bitter melon in English, is a fast growing vine belonging to cucurbitaceae family. It has received attention because it produces RIPs that possess immunomodulatory, antitumor, anti-viral, anti-human immunodeficiency virus (HIV) and abortifacient activities [13] . This review focuses on the physical, biological and biophysical properties of Momordica charantia RIPs and their effectiveness in establishing anti-viral therapy.
EARLY HISTORY

Discovery
In 1978, two lectins were isolated from Momordica charantia inhibited protein synthesis in Ehrlich ascites cells and subsequently named agglutinin and momordin [14] . A haemagglutinating lectin purified from the seeds of M. charantia inhibited protein synthesis in a cell free system (rabbit reticulocyte lysate) and was found to be less toxic to animals than the best known RIP ricin from Ricinus communis (castor bean) [15] . In 1981, it was reported that M. charantia contained an antiviral protein (Momordica charantia inhibitor [MCI] ) that inhibits protein synthesis by cell free system with little effect on intact cells and reducing the infectivity of tobacco mosaic virus [16] . The M. charantia plant was found to contain more proteins that possessed biological properties like RIPs. Many researchers have isolated various proteins from M. charantia but the best studied RIPs are MAP30, -and -momorcharins, known to possess anti-HIV, anti-HSV properties.
General Characteristics of RIPs
Alpha and Beta Momorcharins
Some general properties of M. charantia RIPs are mentioned in Table 1 . The molecular weight of M. charantia RIPs has been reported to range from 10 [17] to 115 kDa [15] . Alpha and beta momorcharins (MMCs) are two RIPs that are isolated from seeds of M. charantia. MMCs are basic single chain glycoproteins, and appear to have two related forms. -Momorcharin has molecular weight approximately 30 kDa and a neutral sugar content of about 1.6%. ß-momorcharin is a 29 kDa glycoprotein having a neutral sugar content of about 1.3%. Both momorcharins lack haemagglutinating (lectin) activity.
-and ß momorcharins possess similar structure and biological properties, but are immunologically distinct [18] . Their biological activities include induction of mid-term abortion [19, 20] , inhibition of tumor growth, suppression of immune response [21] and inhibition HIV-1 [22] .
Although MMCs and other RIPs such as Ricin Achain and Abrin A show strong homology in their primary structure, but there was no evidence to support the data whether the MMCs have ribosome inactivating properties. In 1988 Yeung et al. [23] reported that MMCs with abortifacient activity inhibit cell free protein synthesis with potency similar to that of known RIPs. Besides RIP property, -and ß-MMC exhibited deoxyribonucleolytic activity [24] and ribonuclease activity [25] . The amino acid sequence of -momorcharin has 54% homology with -momorcharin [26] . The amino acid composition of the deduced -MMC is high (34-63%) on comparing amino acid of other ribosome inactivating proteins, such as trichosanthin [27] . Both -and -MMCs possessed antifungal activity. -MMC showed antifungal activity against Fusarium oxysporum and Phythium aphanidermatum, while -MMC had antifungal activity against Phythium aphanidermatum [28] .
MAP 30
Another protein which has been extensively studied after and ß-momorcharins from M. charantia is MAP30 (Momordica Anti-HIV Protein). It was isolated from seeds of M. charantia in a similar manner as that of -and -momorcharins. The protein was purified by ion exchange and gel filtration chromatography. The MAP30 eluted in a linear NaCl gradient, expressed anti-HIV activity [29] .
Structurally, MAP30 is a single chain protein containing 263 amino acids residues with 30 basic amino acid residues that account for approximately 11% of the total amino acids and its basic pH. The molecular weight of MAP30 is 30 kDa [30] . Biological activity of this protein includes inhibition of in-vitro protein synthesis (ribosome inactivation), anti-tumor, anti-microbial, anti-viral and anti-HIV replication [31] .
Expression of Recombinant MAP30 Protein
Genomic and cDNA clones encoding MAP30 from M. charantia are cloned based on knowledge of partial amino acid sequences. Oligonucleotides primers designed from these sequences are used in the polymerase chain reaction to specifically amplify the MAP30 protein genes [30] . The MAP30 gene has also been cloned into a prokaryotic expression vector pET28a using PCR method for rapid identification of positive clone [32] .
Recombinant MAP30 (rec-Map30) was expressed in common edible cucurbits plants and their fruit such as squash, cucumber, melon and pumpkin offers readily available orally bioactive alternative food source for this antiviral protein. Zucchini Yellow Mosaic virus-AGII (ZYMV-AGII), used as a plant virus vector to direct expression of the MAP30 to the fruit [33] . Squash leaves inoculated with viral vector containing MAP30 developed lesions on their leaves indicative of MAP30 expression. Antiviral activity of the MAP30 purified from squash leaves (MAP30-SQ) against HIV, HSV and HHV8 viruses was determined and found identical in inhibiting viral propagation to the naturally derived MAP30. MAP30-SQ also showed antimicrobial activity against bacteria, yeast and fungus [33] .
Recently, effect of rec-MAP30 on cell proliferation and apoptosis of human colorectal carcinoma LoVo cells has also been reported [34] . Proliferation of LoVo cells was inhibited by rec-MAP30 in time and dose dependent manners. MAP30 induced accumulation of cells arrested at G1 and S phases of the cell cycle, a result from multiple mechanisms of action such as inducing apoptosis by down-regulation of anti-apoptotic Bcl-2 and interfering with cell cycle progression.
Chemical Modifications of MAP30
Chemical modification studies were performed on MAP30 by reacting targeted amino acid residues of the peptide with an organic derivatizing agent capable of reacting with selected side chains or terminal residues. It has been found that such derivatized moieties improved the solubility, absorption and biological half life of the MAP30. Arginine residues were modified by reaction with phenylglyoxal, 2-3 butanedione, 1-2 cyclohexanedione and ninhydrin. Derivatization of lysine was carried with reagents such as succinic or other carboxylic acid anhydrides which reversed its charge. Other modifications include hydroxylation of proline, phosphorylation of hydroxal groups of seriene or threonine residues, methylation of the alpha-amino groups of lysine, arginine and histidine side chains, acetylation of the N-terminal amine and amidation of the C-terminal carboxyl groups [35] .
-Momorcharin
A low molecular weight RIP, -momorcharin (11.5 kDa) isolated from the seeds of M. charantia has RNA N-glycosidase activity. While -and -MMC had neutral sugar content 1.6 % and 1.3 % respectively, -momorcharin contained no neutral sugar. It did not exhibit superoxide dismutase and endonuclease activity because limited amino acid residues were not enough to construct other active sites for these activities [36] , while camphorin, a single chain RIP from Cinnamomum camphora had RNA N-glycosidase endonuclease and superoxide dismutase activity [37] . This demonstrates that the limited amino acid residues of -momorcharin are not enough to construct other active sites.
-and -Momorcharins
The RIPs, -momorcharin and -momorcharin were isolated from seeds and fruits of M. charantia respectively. -Momorcharin with a molecular weight of 30 kDa which is slightly larger than those of -andMMCs. -Momorcharin had molecular weight of 24 kDa, which was on the lower side of the range of molecular weight (24-32 kDa) reported for RIPs. The cell free protein synthesis inhibition by -momorcharin was much weaker than the existing M. charantia RIPs whereas -Momorcharin, appeared as active as -and -MMCs in cell free protein synthesis inhibition [38] .
Ribonuclease MC
A new 22 kDa ribonuclease (RNase-MC) protein, which has ribosome inactivating property, was isolated from the seeds of M. charantia. Both -and -MMC, two RIPs also present in the same seed extract, possessed RNase activity, but to a less extent as compared to RNase-MC [39] . Complete amino acid sequence analysis reveals, RNase-MC was found to contain 191 amino acid residues which were 41% homologous to Nicotiana alata S-glycoprotein [40] . Crystallization of RNase-MC obtained by the hanging drop vapor diffusion method revealed that crystal belonged to the orthorhombic space group and contained one monomer of RNase-MC per asymmetric unit cell [41] .
MRK29
A bitter gourd protein (MRK29) isolated from ripe fruit (M. charantia) in Thailand has ~29 kDa molecular weight. The purified protein inhibited HIV-1 reverse transcriptase and reduction of viral core protein p24 expression in HIV-infected cells. The protein was thought to have immunomodulatory role on immune cells, because it increased 3-fold TNF cytokine activity [42] .
Charantin
A small "napin" like ribosome inactivating peptide charantin (9.7 kDa), was isolated from M. charantia seeds. Napins belong to the family of 2S albumin seed storage proteins and consists of two subunits linked by disulphide bridges. Charantin is a single peptide chain, unlike other napin like proteins, which are composed of small and large chains. No biological activity yet has been reported for bitter gourd napin like protein [17] . Contrary to native napin-like protein, recombinant napin (His-rMcnapin) exhibited high antifungal activity against Trichoderma humatum when compared with mature napin-like proteins from M.charantia. The refolded recombinant protein exhibited ~90% activity against plant pathogenic fungi suggesting proper and efficient folding of recombinant protein [43] .
Hypothetical RIP
We have recently identified a novel species of Momordica which has been found to possess low molecular weight protein. The purified protein from novel species has ~28 kDa molecular weight and possesses significant expression [44] . To confirm function of purified protein (named "hypothetical RIP") which resembles existing RIPs further work is under progress [45] .
ENZYMATIC FUNCTION
Glycosidase Activity
RIPs from M. charantia depurinates intact ribosomes in exactly the same manner as ricin A-chain does. Ricin, a toxic RIP, isolated from seeds of castor bean (Ricinus communis) was the first protein whose biological activity was ascribed to plant protein. Approximately 50% of the A-chain consists of -helices and ß-sheets. The B-chain of ricin is a bilobal structure composed of two homologous domains. Endo and Tsurugi [6] reported that ricin A-chain removed a single adenine residue from position 4324 in the 28S rRNA of rat liver ribosomes, defining RIPs as ribosome specific N-glycosidases. Depurination occurs at a highly conserved stem-loop structure found in the large RNA of all ribosome. Ricin recognizes a highly conserved region in the large 28S rRNA and cleaves a specific Nglycosidic bond between an adenine and the nucleotide on the RNA whereby the adenine residue is removed. The depurinated adenine is in the highly conserved sequence context of GAGA, shown to be involved in ribosome-elongation factor interaction ( Fig. 1) [6] . After the removal of adenine, the deadenylated site becomes unstable and a -elimination reaction can occur after the RNA is treated with acidic aniline, whereby the 3'-end of the rRNA is cleaved and can be detected by electrophoresis. This site is usually depicted as being present in a single-stranded loop, called the sarcin/ricin loop. It is located in domain VII, some 400 nucleotides from the 3'-end of the rRNA [7] . This particular sitespecific RNA N-glycosidase activity is a common property of all identified type I and type II RIPs.
-and -MMC damaged eukaryotic ribosomes by acting catalytically in a similar manner as the A-chains of ricin [23] . Another study showed that the action ofand -MMC on rRNA was very specific with MMCs acted only on the 28S rRNA, but not on 18S, 5.8S and 5S rRNA, to release the RNA fragment (Endo's fragment) upon acidic aniline treatment of the isolated rRNA. The N-glycosidase activity of the MMCs was not affected by a change in pH from 6.5-9. The enzyme activity of MMCs increased as the concentration of [K + ] was raised up to 0.1M. The enzyme activity of -MMC fluctuated slightly with the increase in the concentration of [NH4 + ] from 0.1-0.25M. A significant inhibitory effect of Mn 2+ on the activity of -MMC was observed [46] . A similar effect was observed on -sarcin (cytotoxic protein from Aspergillus giganteus) [47] .
-Momorcharin also exhibited RNA N-glycosidase activity on ribosomes isolated from rat liver. The production of the RNA fragment was dose dependent. To determine the action site of -momorcharin on 28S rRNA, the sequence of 5'-terminal nucleotides of the RNA fragment produced by -momorcharin/aniline treatment was analyzed. This was carried out because both the complete sequence of rat 28S rRNA and the 5'-terminal nucleotide sequence of the RNA fragment produced by ricin A/ aniline treatment are already known. By comparing the 5'-terminal nucleotide sequence of RNA fragment produced by -momorcharin with ricin nucleotide sequence, it can be concluded that -momorcharin acts on the same active site on the 28S rRNA of rat liver ribosome as ricin Achain does [6, 7, 36, 48] .
-Momorcharin exhibited N-glycosidase activity and released a specific RNA fragment of ~400 nucleotides from 28S rRNA. -Momorcharin exhibited weak Nglycosidase activity as compared to other existing RIPs [38] . Charantin, reacted positively in the N-glycosidase assay. Charantin produced 470bp fragment, when treated with rabbit reticulocyte lysate. This product band was similar to the small RIPs like -momorcharin and luffin-S (a RIP isolated from Luffa cylindrica) [17, 49] .
Inhibition of Protein Synthesis
M. charantia RIPs were found to be potent inhibitors of protein synthesis in cell free system ( Table 2) . M. charantia lectin is the second example of a non-toxic lectin, inhibiting protein synthesis in-vitro, after Ricinus communis agglutinin [50, 51] . In 1979, M. charantia lectin was found to be a potent inhibitor of protein synthesis in cell free system (a lysate of rabbit reticulocyte) [52] . After lectins, -and -MMCs are known to inhibit protein synthesis in cell free system (rabbit reticulocyte lysate). The potencies of the cell free protein synthesis inhibitory activity by -andMMCs were reported as ID 50 0.12 nM and ID 50 0.11nM respectively [23] .
MAP30 exhibited a dose dependent inhibition of cell free translation system [29] . The effect of MAP30 on Fig. (1) . Mechanism of action of RIP: A specific N-glycosidase activity cleaves adenine (A4324) which is located in sarcin/ricin loop of the ribosomal RNA of the large subunit. The reaction product of the RNA N-glycosidase (Deadenylated rRNA) acts as a substrate for 'ribosomal RNA apurinic site specific lyase' (RALyase), which cleaves the phosphodiester bond 3' end. The reaction products are a short (4325-4785) 3'-end fragment and a long (1-4324) 5'-fragment with free 3'-hydroxyl terminus. [30] .
-Momorcharin inhibited protein synthesis in a dose dependent manner in rabbit reticulocyte lysate assay. It exhibited higher ID 50 (55nM) value. The higher ID 50 value may be due to the small molecular mass of this RIP in inhibiting protein synthesis [36] . The potency of -momorcharin in inhibiting cell free translation in rabbit reticulocyte lysate was similar to -and -MMC. Such proteins displayed a translation inhibiting activity with an ID 50 of 0.15 nM. -Momorcharin exhibited much weaker inhibition of cell free protein synthesis than the existing RIPs. The ID 50 value of -momorcharin was 170 nM [38] . Charantin inhibited cell free protein synthesis with an ID 50 of 400 nM [17] .
STRUCTURE-FUNCTION RELATIONSHIP
The first three dimensional structure of ricin was solved by X-ray crystallography and refined to 2.8 resolution [53] . This structure is archetypical for other RIPs. The overall structure of ricin is glycosylated, globular, heterodimer with the monomer units joined by a single disulfide bond ( Fig. 2A) . The ricin A-chain is a 267 residue globular protein, structured from three domains, with approximately 50% of the polypeptide arranged into -helix or -sheet. Ricin A-chain has a pronounced active site at the interface of the three domains, which is able to recognize and accommodate the r RNA stem-loop which is its main target. The ricin B-chain comprising 262 amino acid residues, is a two domain structure. Each ricin B-chain domain has galactose binding site lying in a pocket formed in part by a kink in the polypeptide chain by the tripeptide AspVal-Arg.
-MMC structure was solved by X-ray crystallography using multiple-isomorphus-replacement methods and refined at 1.6-2.2 resolution [54] . It consists of 250 amino acid residues and has three domains. Domain one and domain two are associated and form a large domain, which consist of residue 1-202 and a small domain, which was near the C-termini. These two domains form an apparent cleft at their interface on the surface of protein.
-MMC consists of eight -helices and -sheets. Helix 2 1 is a very short helix with only seven residues near the C-terminus. Hydrophobic interactions, ion-pairs and hydrogen bonds have been observed between main chain atoms or side chain atoms. These interactions stabilized whole folding and secondary structure of the protein.
Active centers residues are from 69-71, 83-85, 108-114 and 155-163. The residues from 189 to 192 form the outer edge of the catalytic centres. These residues have been located near helices 1 2 , 1 3 and 1 4 and near 1 4 , 1 5 and 1 6 respectively. Conserved residues Tyr-70, Glu-160, Arg-163 and Trp-192 form active centres and the side chain of these two residues form the opening of the binding pocket. Some conserved residues in protein, which are not directly involved in forming the active centres, like Phe-4, Tyr-14, Phe-17, Arg-22, Leu-52 and Arg-122. These residues involved in the stabilization of the geometry of active centers (Fig. 2B ).
-MMC structure is the first example among RIPs, which gives information about the three-dimensional structure and binding site of the oligosaccharide in the active chains of RIPs (Fig. 2C) . The crystal structure of -MMC protein was determined using the molecularreplacement method and refined to 2.55 resolution [55] . -MMC has 249 amino acid residues and contains nine -helices, two 3 10 helices and three -sheets with a total of ten -strands. The polypeptide chain folds into two domains, a large N-terminal domain (Asp1-Asn180) and a smaller C-terminal domain (Leu181-Asn 249). Active site residues Tyr-70, Tyr-109, Glu-158 and Arg-161 are expected to be associated with rRNA Nglycosidase activity.
-MMC molecule contained branched hexasaccharide, which are composed of two -N-acetylglucosamines [GlcNAc(1) and GlcNAc(2)], one -fucose (Fuc), one -mannose [Man (1)], onemannose [Man (2)] and one -xylose (Xyl). The oligosaccharide is bound to Asn-51 through Nglycosidic bond [ -GlcNAc-(1-N)-Asn-51] and stretches from the surface of the N-terminal domain far from the active site, suggesting that it should not play a vital role in the enzymatic function. The oligosaccharide molecule interacts with -MMC through hydrogen bonds, although in the crystals most of these are intermolecular interactions with the protein atoms in the adjacent unit cell.
A MAP30 structure was solved by NMR [56] . The Nterminal domain (residues 1-105) contains an extended mixed sheet of six -strands. Strand 3 contains the Nlinked glycosylation site, Asn51-Leu52-Thr53, in which one face of this sheet packs against -helices in the highly helical central domain i.e residues 108-180 of the molecule. The C-terminal domain, residues from 181-263 contains structured region, in which the long bent helix, residues from 181-200 packs against an antiparallel two-stranded -sheet (Fig. 2D) . The residues Tyr-70, Tyr-109, Glu-158 and Arg-161 are known to be responsible for RNA N-glycosidase activity and located in a deep pocket that specifically accommodates an extra helical adenine base. MAP30 RNA N-glycosidase pocket is located in the middle of a groove that runs along one side of the protein. The surface of the groove is negatively charged with residues Glu-110, Glu-121 and Glu-187 to the right and residues Asp-43, Asp-65, Glu-85 and Glu-89 to the left of the RNA N-glycosidase pocket. Based on structural homology of MAP30 similar groove was found in ricin A-chain and hypothesized that this groove was a binding site for DNA substrates [57] .
The sharing of a common enzymatic activity i.e RNA N-glycosidase activity by ricin A-chain with M. charantia proteins suggests that they are structurally related. Comparison of the N-terminal amino acid sequence indicates that MAP30 and -MMC share only 48% amino acid homology ( Table 3 ). The sequence of -MMC was different from that of -MMC in 10 out of the 20 positions. Instead, -MMC shows a high homology to MAP30. The only difference resided in position 14; the tyrosine in -MMC was replaced by a threonine in MAP30. It is also observed that MAP30, MRK29, -and -MMC show identity with ricin A-chain.
ANTI-TUMOR ACTIVITY
The RIPs from M. charantia have been shown to possess in vitro and in vivo anti-tumor activity. MAP30 exhibited anti-tumor activity against certain human tumor cell lines from renal, non small cell lung and breast cancer. The most sensitive cell lines responded to MAP30 with ID 50 ranged from 0.01 to 10 g/ml and was unrelated to tumor type [58] . To draw comparisons with nMAP30, anti-tumor activity of rec-MAP30 was studied on several human tumor cell lines like brain glioblastoma, breast carcinoma, epidemoid carcinoma, liver hepatoma, melanoma, myeloma, neuroblastoma and prostate carcinoma. The anti-tumor activity of rec-MAP30 and nMAP30 were identical with respect to their sensitivity to particular tumor types. The most sensitive tumor cell lines were breast, CNS, melanoma and myeloma tumors with ID 50 MAP30 has preferential cytotoxicity for human leukemia cells, being at least 10 times more potent and killing specifically leukemia cells compared to normal human peripheral blood lymphocytes. MAP30 also showed in vivo anti-tumor activity against estrogenindependent and highly metastatic human breast tumor [59] . The concentrations used for in vivo treatment were reported non toxic to the mice over the period of treatment [35] .
Recently, we have shown that natural bioactives like 100% iron saturated bovine lactoferrin (Lf+) acts as potent natural adjuvant and fortifying agent for augmenting cancer chemotherapy [60, 61] . Such natural components along with RIPs can be used as a complementary and alternative medicine. Our studies indicated that Lf+ was more effective than natural bLf at inhibiting tumourigenesis, and augmenting chemotherapy, when given orally to C57BL/6 mice for several weeks prior to cancer chemotherapy, and eradicated large (0.5 to 0.6 cm diameter) lymphoma (EL-4), lung cancer (Lewis lung carcinoma), and melanoma (B16) tumours. Our in vitro, study further revealed the significant increase in the cell cytotoxicity and apoptosis in the human colon cancer cells (CaCo2, in Lf+ and Se-bLf (selenium saturated bLf) (100-300μg/ml) treated cells. Interestingly normal FHS74-Int cells remained unaffected or resistant at these concentrations [62, 63] . Similar studies are proposed with RIPs from Momordica sp in combating cancer as reviewed earlier by us [64] .
ANTIVIRAL PROPERTIES OF RIPs
M. charantia proteins possess broad spectrum antiviral properties against different viruses ( Table 4) which include RNA and DNA viruses through inhibition of viral protein synthesis in the infected cells. The observations that M. charantia proteins were effective against a number of different viruses coupled with its ability to inactivate eukaryotic ribosomes in vitro, clearly suggested that the mechanism of anti-viral action in all cases could well be due to the inactivation of host ribosomes in virus infected cells.
Effects on Human Immunodeficiency Virus (HIV) Infection
MMCs and HIV
-and -Momorcharins were the first RIPs isolated from Momordica charantia seeds and studied for anti-HIV activity. Both -and -momorcharins inhibited HIV antigen expression in HIV-infected human T-cells and monocytes/macrophages, when tested as an improved drug therapy for treating HIV-infections in humans [18] . -MMC showed complete inhibition of reverse transcriptase (RT) activity in HIV infected cells and this inhibition was achieved at concentrations of anti-viral protein at which healthy (uninfected) cells were largely unaffected. -MMC also inhibited viral replication. Several reverse transcriptase inhibitors, including ribavarin, phosphonoformate, phosphonoacetate and azidothymidine, produced only partial inhibition of viral core protein p24 expression in comparison to MMCs [22] . On treatment of HIV-infected monocytes with MMCs, a complete inhibition of p24 expression was observed. There was a complete inhibition of HIV antigen expression in infected monocytes at lower effective dose concentrations (0.5 or 5μg/ml) that produced only a slight reduction in cell viability. In HIV patients, these anti-HIV proteins (MMCs) inhibited other events related to the loss of immunological competence in HIV infected individuals, through general suppression of virus levels and inhibition of viral protein synthesis in infected cells. -MMC may be administered parenterally, including liposomeencapsulated form, solution form and attached to a carrier, such as an anti macrophage, anti T-cell or anti-HIV antibody for targeting the protein to HIV infected cells.
Intramuscular placement of liposomeencapsulated protein or protein trapped in a collagen matrix will provide slow release of the drug into the blood stream, the possibility of greater viral inhibition and reduced toxicity [22] . Another RIP, Trichosanthin (TCS from Trichosanthes kirilowii) also has similar anti-HIV property as -and -MMCs and inhibited the expression of HIV in cells isolated from infected individuals [65] . The observation that TCS, -andMMCs and other RIPs had anti-viral activity generated an interest in the anti-viral properties of RIPs for Residues identical to ricin A-chain are underlined.
potential therapeutic applications as anti-HIV agents. The early study that RIPs had anti-HIV activity led to investigations of plants known to contain large amount of RIPs such as gelonin, dianthin, pokeweed anti-viral protein and other plant cytotoxins [16, [66] [67] [68] . Following, this a number of proteins were purified and characterized from plants that had potent anti-HIV activity when tested against HIV. These proteins were named anti-HIV protein like TAP29, MAP30, GAP30, DAP30 and 32 and many more with the addition of a digits representing molecular weight of the protein. All these proteins exhibited anti-HIV activity and inhibited protein synthesis by acting on ribosomes [29, [69] [70] .
MAP30 and Immunodeficiency Virus
In 1990, MAP30 was isolated and purified to homogeneity from the seeds and fruits of the M. charantia for the first time and its effect on anti-HIV-1 activity was studied [29] . MAP30 exhibited dosedependent inhibition of cell-free HIV-1 infection and replication as measured by: (i) quantitative focal syncytium formation on CEM monolayers; (ii) viral core protein p24 expression; and (iii) viral-associated reverse transcriptase (RT) activity in HIV-1 infected H9 (human T cell line) cells. The doses required for 50% inhibition (ID50) in these assays were 0.83, 0.22 and 0.33 nM, respectively. No cytotoxic effects were observed under the assay conditions. MAP30 showed no inhibition of cellular DNA synthesis and protein production at 33.4nM, a concentration where 98% and 87% inhibition of p24 and RT activity respectively was achieved [29] . In comparison to trichosanthin (renamed as GLQ223) MAP 30 was much less cytotoxic and had a much better therapeutic index than GLQ223.
More importantly, MAP30 was shown to improve the efficacy of anti-HIV therapy when used in combination with low pharmacological doses of steroidal and antiinflammatory drugs like dexamethasone (DEX) and indomethacin (IND) respectively. The combination of non-toxic 1.5 nM dose of MAP30 either with DEX or IND resulted in a reduction in p24 expression in acutely infected MT-4 lymphocytes. MAP30 was able to reduce the ID 50 of the steroid dexamethasone or indomethacin by about 1000 fold. Whereas other non-steroidal antiinflammatory drug (NSAID) when used in combination with MAP 30 did not show anti-HIV activity and alter ID 50 of AZT (3'-azido-3'-deoxythymidine) [71] . Rec-MAP30 exhibited similar anti-HIV activity as shown by natural MAP30 (nMAP30). The ID 50 of both rec-MAP30 and nMAP30 were nearly identical at between 0.2 nM and 0.3 nM for syncytium formation, p24 inhibition and RT inactivation. Both nMAP30 and rec-MAP30 showed dose-dependent inhibition and like nMAP30, re-MAP30 was also non toxic to uninfected H9 cells and had no effect on cellular DNA and protein synthesis [30] . Only MAP30 (both nMAP30 and rMAP30) possesses dual ability to act on both RNA and DNA substrates. Interestingly, rec-MAP30 had shown a unique activity that affects topologically inter-conversion of viral DNA and interrupts its function. Rec-MAP30 was capable of irreversibly relaxing HIV-1 supercoiled DNA and catalyzing double-stranded breakage to form topologically inactive products. The viral DNA topological inactivation and HIV-1 integrase inhibition by rec-MAP30 does not appear to be universal property of all RIPs [30] .
On further investigating the role of MAP30 on HIV-1 integrase, it is known to bind to HIV-1 DNA and catalyzes the insertion of the viral genome into the host. The first activity studied was integrase-mediated 3'-processing of the viral LTR's (Long terminal integrase). LTRs are essential sites for integration of viral DNA into the host genome by viruses. MAP30 when added to in vitro reaction was able to completely inhibit the processing at equimolar concentrations. Using pUC18 as a target for insertion, the integration reaction of the labeled nucleotide (strand transfer) was monitored (by the conversion of unlabeled plasmid to the labeled DNA) in the presence of MAP30. MAP30 exhibited dose-dependent inhibition on the strandtransfer activity of HIV-1 integrase, and total inhibition was observed at stoichiometric concentrations of the HIV inhibitor and HIV integrase. The disintegration reaction, where the inserted genome is excised from the target, was also studied. Strand cleavage takes place precisely at the junction between the viral and the target sequences and is coupled to the rejoining of the cleaved target sequences. Inhibition was studied by using oligonucleotides substrates with sequence corresponding to U5 regions of HIV LTR. Thus the inhibition of disintegration by MAP30 may also affect catalytic recycling of the HIV-1 integrase [72] .
The anti-viral agent, MAP30 was found to be non toxic to human sperms at the doses known to inhibit HIV-1 replication. It had no effect on the motility and vitality of human spermatozoa [73] . The proteolytic fragments of MAP30 were also found to be biologically active [31] . During protease digestion, the central fragments of the MAP30 were protected from proteases presumably by the rigid and compact nature of the RIP. The N-and C-termini of MAP30 were more susceptible to cleavage. Three major proteolysis fragments were generated, out of which the two largest fragments retained anti-HIV activity (MW of 21-22 kDa and 25-26 kDa). The ID 50 values of fragments for anti-HIV activity were similar to the parent MAP30, namely between 0.2 nM and 0.4 nM. The central proteolytic fragment prevented HIV-1 integrase, topologically relaxed supercoiled DNA and inhibited HIV-1 and p24 expression. These proteolytic fragments were neither cytotoxic nor inhibitory to cell-free translation, unlike the full length RIP (MAP30). Interestingly, N-and C-termini of MAP30 were not necessary for activity against HIV-1, but are required for ribosome inactivation [31] suggesting that the antiviral activity of MAP30 is independent of their ribosome inactivation activity.
MRK 29
Anti-HIV activity was also observed in MRK29 from Thai bitter gourd. Partially purified MRK29 inhibited the HIV-1 reverse transcriptase (RT). At 6 nM, it showed 82% reduction of viral core protein p24 expression in HIV infected cells while 630 nM of crude MRK29 could inhibit HIV-1 RT by 50% [42] .
Blood-Brain Barrier (BBB) and Action on Viral Reservoirs In Vivo by RIPs
Human immunodeficiency virus type I (HIV-1) crosses the blood brain barrier (BBB) to induce brain dysfunction. How do HIV-1 crosses the BBB is unclear. The viral coat glycoprotein 120 (gp120), may facilitate the passage of HIV-1 and HIV infected immune cells across the blood brain barrier [74] . M. charantia RIPs have not been shown to cross the blood brain barrier (BBB) and their antiviral activity in the brain is unknown. RIPs in the blood stream can target on HIV or other virus loaded immune cells to induce viral clearance. Regarding other viral reservoirs of HIV patients, these RIPs could target viral integration, viral replication and hence will prevent infection of new cells but will not affect the established reservoirs. HIV-1 infects the CNS and it has been feared that the CNS may be a sanctuary site where HIV-1 could hide and continue to replicate despite otherwise effective antiretroviral treatment [75, 76] . To know the possibility that M. charantia RIPs' penetrate through the bloodbrain barrier (BBB) is central to the design of new central nervous system (CNS) active M. charantia RIPs based anti-HIV therapeutics.
TCS (trichosanthin) from
Trichosanthes kirilowii maximowiz is a type 1 RIP effective against HIV-1 and HSV-1 replication. The protective effects of TCS were studied on infectious brain injury induced by herpes simplex virus-1 (HSV-1) in mice [77] . Viral encephalitis was induced by intracranial inoculation of HSV-1 and TCS was injected before 30 min of HSV-1 inoculation to TCS-treated mice group. TCS treatment led to lower water content of brain tissue, higher neurological deficient scores after 24 h of HSV-1 inoculation and noticeably lower viral titer of brain tissue than that in model group after 7 d of HSV-1 inoculation.
More recently, in unprecedented experimental evidence it has been shown that other RIPs such as Pokeweed Anti-viral Protein (PAP) cross blood brain barrier and exhibited anti-viral activity within the CNS [78] . In a murine model of Lymphocytic Choriomeningitis Virus (LCMV) significant efficacy of Pokeweed Anti-viral Protein (PAP) was described. LCMV infection is a significant, often unrecognized cause of chorioretinitis, hydrocephalus, microcephaly or macrocelphaly as well as mental retardation and aseptic meningitis or meningoenceophalitis are the predominant syndromes. Treatment of CBA mice with PAP significantly improved the probability of survival following the LCMV challenge and decreased overall LCMV-related symptoms. The ability of PAP to exhibit anti-viral activity within the CNS is also encouraging within the framework of potential HIV-treatment with M. charantia RIPs [78] . Further in inflamed brain in neurotrauma, multiple sclerosis and brain tumours patients where blood vessels are leaky [79] , these RIPs can cross along with the reactive immune or tumour cells and may have a protective role in clearing virus particles or tumours.
Effects on Herpes Simplex Virus
HSV-1 is an enveloped DNA virus and is the causative agent of several types of primary and recurrent diseases including gingivostomatitis, herpes labialis (cold sores), keratoconjunctivities and encephalitis. M. charantia inhibitor (MCI) had shown inhibition of herpes simplex virus type1 (HSV-1) multiplication which was reduced in a similar manner to PAP (from Phytolacca americana) [80] . The yield of HSV-1 was reduced on incubation of the infected cells with MCI. The inhibition of HSV-1 replication by MCI implies that it might be acting during the intracellular reproductive cycle and on protein synthesis, which inhibited more markedly in virus-infected than in control cells [81] .
Symptomatic infection especially with HSV-2 is common among individuals infected with HIV. In HIV patients, HSV infections are much more frequent, severe and life-threatening. However in immunocompetant individuals, HSV rarely causes mortality. HSV infection causes more mortality and morbidity in AIDS patients than any other viral pathogen. Acyclovir (ACV, a HSV specific nucleoside analog) is used for treating HSV infections in HIV patients and HSV becomes resistant to ACV due to alteration in the viral DNA polymerase or mutation of the viral enzyme thymidine kinase [82] . Another attraction of MAP30 is that it was found to be effective against HSV-1, HSV-2 as well as an ACV-resistant HSV strains. MAP30 was found to be effective against HSV-1, HSV-2 as well as an (ACV)-resistant HSV strains. These mutants are unable to phosphorylate ACV to ACV triphosphate, the active form of the antiviral drug. ACV triphosphate is an inhbitor of HSV DNA polymerase [83] . At 0.3 M concentration of MAP30, no loss of viability was observed in infected WI-38 cells (embryonic lung fibroblast cell line) and displayed similar toxicity profile as that of ACV. At 24 h postinfection with HSV, the cells started to display cytopathic changes, unless MAP30 was added during the incubation with virus. The ID 50 for MAP30 was between 0.1 to 0.3 μM in both ACV-sensitive and resistant strains of HSV-1 and HSV-2. In H9 cells a concentration (0.3 μM), only 25% inhibition of protein and DNA and protein synthesis was observed. It is interesting that MAP30 (EC 50 μM) demonstrated an exceptionally high activity against wild type HSV-2 strain, which is about 20-fold more potent than ACV. This implies that the anti-HIV protein may also be active against both wild type and ACV-resistant HSV strains [81] .
Effects on Poliovirus
Poliovirus is a non-enveloped positive-strand RNA virus that infects animal cells and causes a debilitating neuromuscular disease in humans. The virus does not bud from the cell; instead they accumulate in the cytoplasm and are released when the cell bursts. M. charantia inhibitor (MCI) inhibited multiplication of poliovirus I in HEp-2 cells. Since Poliovirus was thermostable during a 24 h incubation period either in the absence or in the presence of the RIP, this rules out that the reductions in virus yield in the presence of the inhibitory protein was due to the inactivation of infectivity of progeny virions. It was also demonstrated that the reduced multiplication of poliovirus was not due to an inhibition of protein synthesis in infected cells [80] .
Effects on Kapsoi Sarcoma-Associated Herpes Virus
A MAP30 inhibited the proliferation of BC-2, an AIDS-related primary effusion lymphoma (PEL) cell line derived from an AIDS patient [84] . BC-2 cells are latently infected with Kaposi sarcoma-associated herpes virus (KSHV), also known as human herpes virus 8 (HHV8). MAP30 caused a dose-dependent inhibition of BC-2 cell proliferation with an EC 50 of 0.3 to 0.6 nM and was equally effective against lytic and latent states of virus. The HHV8 genes vCD, vFLIP and vIL-6 are among the few viral genes expressed in BC-2 tumor cells, which play key roles in oncogenesis and cellular transformation. RT-PCR and northern blot analysis showed that MAP30 blocks the expression of these viral genes. MAP30 also altered the expression of both viral and cellular genes involved in KS pathogenesis and may have significant therapeutic potential in the treatment of AIDS-related tumors [84] . From cDNA microarrays analysis for the expression profile of 92 specific cellular genes involved in cell cycle regulation, apoptosis and cytokine signaling in AIDS-related tumor cells, twelve genes were found to be expressed at high levels in both latent and lytic phases of the viral life cycle. These were ATF-2, egr-1, hsp27, hsp90, I Ba, IL-2, mdm2, caspase-6, caspase-10, NIK, TNFR2 and Skp1 and microarray analysis indicated that MAP30 down-regulated significantly the expression of 11 of the 12 cellular genes involved in Kaposi's sarcoma (KS) pathogenesis, while it down regulated slightly the expression of IL-2. MAP30 upregulates specific genes related to apoptosis, including Bax, caspase-3 and CRADD, interfering with the viral program to suppress apoptosis [84] .
There are no reports on RIPs-drug-drug interactions. However, RIPs can be combined with highly active anti-retroviral treatment (HAART) or other antiviral molecules to boost the arsenal power by inhibiting the viral integration step [85] .
IMMUNOSUPPRESSIVE ACTIVITY
-and -MMCs were reported to be potent modulators of a variety of cell mediated and humoral immune responses, both in vitro and in vivo [21] . In vitro studies have shown that MMC at non-cytotoxic concentrations (50-100 g/ml) caused maximum suppression of mitogen-induced and alloantigeninduced lymphoproliferation, however, did not affect the cytolytic activity of natural killer (NK) cells or cytotoxic T-lymphocytes (CTL) activity. In vivo activation of NK cells was not significantly affected by treatment of mice with -and -MMCs, whereas similar treatment of mice resulted in a significant depression of the delayed type hypersensitivity (DTH) response as well as humoral antibody formation to SRBC (sheep red blood cell). Treatment with MMCs also led to the decrease in the functional capacity of macrophages, such as the cytostatic and phagocytic activities. A single injection of MMC (both and ) did not appear to affect the number of resident peritoneal macrophages but the thioglycollate-induced in vivo migration of macrophages was suppressed. MMC inhibited the production of interleukin-2 from con A-activated mouse splenocyteswhen administered in vivo or present in vitro in culture [21] .
IMMUNOTOXINS AND ANTI-HIV IMMUNO-CONJUGATE
Cytoxic biomolecules and drugs have been exploited for designing immunotoxins (ITs). ITs are chimeric molecules in which cell-binding ligands are coupled to toxins and can specifically eliminate undesired cells [86] . RIPs have been linked to antibodies to form 'immunotoxins' specifically toxic to the tumor cells and viral infected cells [87] . To treat AIDS, the elimination of HIV-infected lymphocytes responsible for the spreading the infection is needed. Two strategies have been used by ITs targeting viral antigens or ITs targeting lymphocytes antigens.
MAP30 was cross-linked to human anti-gp 41 and human anti-gp120 (HIV evvelop glycoprotein)-monoclonal antibodies using the heterobifunctional reagent, SPDP (N-succinimidyl 3-(2-pyridyldithio-) propionate).
The cytotoxic effect of the immunoconjugate was tested on CEM, H9 and V1 cells which had shown specific cytotoxicity for HIV infected, but not for uninfected target cells [88] . Future research should approach the potential use of other RIPs from M. charantia as toxic effectors in the construction of immunotoxins and conjugates for target therapy.
PHARMACOKINECTICS OF RIPS IN VIVO
Bitter melon is an alternative therapy that has primarily been used for lowering blood glucose levels in patients with diabetes mellitus. Some preliminary evidence suggests that the consumption of bitter melon as whole fruit, extract, or dried powder may reduce blood sugar levels. The pharmacology, clinical efficacy, adverse effects, drug interactions, and place in therapy of bitter melon with special focus to diabetes mellitus has recently been reviewed [89] . Data from clinical trials found bitter melon juice, fruit, and dried powder to have a moderate hypoglycemic effect. These studies were small and were not randomized or double-blind, however. Reported adverse effects of bitter melon include hypoglycemic coma and convulsions in children, reduced fertility in mice, a favism-like syndrome, increases in -glutamyltransferase and alkaline phosphatase levels in animals, and headaches. Bitter melon may have additive effects when taken with other glucose-lowering agents. Since these trials were small, brief, and poorly designed and reported, adequately powered, randomized, placebo controlled trials are needed to properly assess safety and efficacy [89] . As for as the antiviral effects of M.Charantia RIPs are concerned, most of data reviewed here is based mainly on in vitro findings. Preclinical in vivo and human research clinical data is very much limited. There exist only two reports based on a human study in 1992 using bitter melon extract administered daily orally or rectally to six HIV positive patients [90, 91] . It has been found that there was improved sense of well being, increased energy levels and CD4+ and CD8+ cells tended to normalize with increased CD4+ cells. Neither the effects on other biomarkers nor toxicity was tested. The study was not controlled or blinded and authors surmise that M. charantia appears to be very promising herbal remedy with low or no toxicity. No follow-up studies by the authors [90, 91] have been reported.
Since studies have displayed the abortifacient and weak uterine stimulant activity of MMCs; therefore use of MMCs during pregnancy is not advocated. Hepatoxicity has also been reported in rodents after oral administration of fruit juice and seed extracts of M. charantia [92] . The serum levels of gamma glutamyl transferase and alkaline phosphatsase were significantly elevated. These increases have not, however, been associated with significant histopathologic changes in the liver. The clinical relevance in humans has not been studied: caution is warranted, particularly in patients with underlying liver disease [89] . Further there may be cellular damage at molecular level or drug metabolizing enzymes such as glutathione-S-transferase in liver as changes in the latter has been described in streptozotocin-induced diabetic rats fed with fruit juice of M. charantia [93] . Future well designed animal and pharmacokinetic studies are urgently needed for the development of RIPs derived from bitter melon as anti-HIV agent and antiviral agents for clinical trials in patients. The recombinant MAP30 protein retains the anti-HIV effects of the natural MAP-30 in the test-tube and has shown minor toxic effects towards normal cells; therefore it can provide an abundant source of homogeneous material for these studies.
CONCLUSIONS AND PERSPECTIVES
Progress in research made in the past decade on the structure, function and properties of M. charantia RIPs has raised hope for utilizing them for various purposes with possible applications in medicine as therapeutic targets as 'immunotoxins', anti-tumor and as antiviral agents, specifically against HIV.
Since the AIDS epidemic began, more than 60 million people have been infected with the virus and it claimed an estimated 2.1 million lives in 2007 of which an estimated 330,00 were children under 15 years. In particular, India (South and South East Asia are second worst affected) is home to 2.5 million HIV/AIDS patients including over 70,000 children below the age of 14 (WHO, 2007) [94] . HIV/AIDS is next to malaria now and is the leading cause of death worldwide. The fatality rate approaches 100% in untreated HIV patients. The emergence of resistance and adverse reactions has also limited the utility of the conventional antiretroviral drugs. As for as RIPs antiviral activities of M. charantia are concerned, MAP30 stands tall among all with its potent activity against HIV-1 which is independent of its ribosome inactivation activity, yet little or no toxicity to uninfected cells. Studies mostly conducted in vitro have aroused interest in the use of bitter melon RIPs in particular MAP 30 as an alternative therapy for AIDS. MAP30 possess multiple therapeutic targets at different stages of the HIV-1 life cycle and is also known to improve the efficacy of anti-HIV therapy in combination with low pharmacological doses of steroidal and anti-inflammatory drugs. Future clinically relevant studies in human primary cells and appropriate animal modes may be better indicators toward the proof of concept in clinical trials. There is further need to study these antiviral RIPs in combination with current arsenal of antiretroviral drugs. In addition, other natural bioactive components such as Lf, which has been reported to have anti-tumor, anti-bacterial and anti-viral activities can be studied in combination with RIPs from M. charantia for more effective alternative and complementary medicine as a neutraceutical in HIV patients and other viral infections. Further compared to type 2 RIPs, all type 1 RIPs tested so far possess antiviral activity against plant, fungal and animal. Since all M. charantia RIPs belong to type 1 RIPs, there is a possibility of broad antiviral activity from the , andMomorcharins which have not yet been tested for the same. Moreover the antiviral activity of all the M. charantia RIPs is yet not completely investigated. Although reported to be independent of the inhibition of cellular DNA and protein synthesis but mechanisms through which these RIPs exert their antiviral activity warrants further investigation. Hopefully, immunotoxins against other cell types will be prepared and used in the treatment for various viral infections. MAP30 is such a RIP, which has manifold biological applications. As MAP30 has anti-viral activity and acted on RNA and DNA observed in vitro, if its action will be observed in-vivo, a direct effect of MAP30 on viral nucleic acid would lead to inhibition to viral infection.
As HIV is a complex virus and develops drug resistance at various stages in its life cycle, it is important to investigate the potential of RIPs in therapeutic intervention in such situations. Importantly, structural information available on RIPs could lead to the development of a whole new series of small HIVinhibitor molecules which could play a significant role in combination-HIV-therapy. However, still profound fundamental knowledge on RIPs is required to design such small molecules of therapeutic value.
Other important areas to investigate--the importance of RIPs to collect epidemiological HIV prevalence data from regions where this vegetable is grown and used commonly in India, China, Africa and Caribbean. It is pertinent to look whether large scale consumption of this vegetable has any impact on modulation of HIV infection. Of note, this vegetable is commonly used in northern India since centuries and whether it provides benefit to that population. Interestingly, within India, southern India has higher HIV prevalency compared to northern India and consumption of this vegetable is very common in northern India. However, other host genetic factors might be playing a role in the prevalence of HIV infection.
Many scientists in various Countries (India, China and USA) are working on developing herbal and Ayurvedic formulations that can treat the dreaded disease HIV/AIDS. Keeping in view anti-viral activities of RIPs from M.charantia, an interesting paradigm emerge which may safely be used in treating viral diseases.
Furthermore, producing RIPs from Momordica sp at Industrial scale would be next step in making such formulations available to growing percentage of HIV infected patients worldwide and establishing its therapeutic credentials.
RIPs cannot cross through BBB in normal humans. However in chronic inflammatory responses such neurotrauma, multiple sclerosis or brain tumour RIPs can cross the BBB because of leaky blood vessels. In these patients RIPs can cross the BBB and can show anti-viral activities. Recent preclinical evidence of PAP to exhibit anti-viral activity within the CNS following LCMV infection is encouraging within the framework of potential studies on HIV-treatment with M. charantia derived RIPs for their actions on latent viral reservoirs in vivo. In addition, smaller active peptides from RIPs may have the capacity to cross the BBB. These active peptides can be identified and isolated for the initial and latent viral infections. vitro, such as antifungal, antibacterial and broad spectrum antiviral activities against human and animal viruses (Stripe et al. 1992 ). RIPs are of great interest because of their potential application in medical biotechnology. Majority of RIPs are found in plant families such as Euphorbiaceae, Phytolaccaceae, Cucurbitaceae and Caryophyllaceae. In the Cucurbitaceae family, several RIPs such as bryodin from Bryonia dioica, luffin from Luffa cylindrica, trichosanthin from Trichosanthes kirilowii, momorcharin and MAP30 from Momordica charantia have been reported and investigated for their potential medicinal usage. Plant RIPs have been shown to possess multiple biological activities such as anti-tumor, anti-human immunodeficiency virus and insecticidal properties . RIPs are also used in crop biotechnology with the aim of increasing resistance to insect, fungal and viral pathogens (Hong et al. 1996) . The A-chains of type-II and type-I RIP have been linked to antibodies to construct immunotoxins that are specifically toxic to the target cell. Immunotoxins are potentially useful in cancer and AIDS therapy (Ramakrishan et al. 1992 ). The type-II RIP ricin has been used as potential anti-cancer agent (Vitetta et al. 1987) . Recently, interest in RIPs has been growing on account of their anti-viral activities (Au et al. 2000) .
ABBREVIATIONS
Momordica balsamina (aka Balsam apple, bitter cucumber or bitter melon) a high-climbing vine from family Cucurbitaceae is native to the tropical regions of Africa, Asia, Arabia and Caribbean. This plant is a monoecious climber and found in India up to an altitude of 300 m. It has been widely used traditionally in Africa to treat various diseases such as diabetes and malaria (Ramalhete et al. 2011) . A nucleic acid sequence submitted from this plant indicating its homology to other proteins with Momordica sp. remained inconclusive (Ortigao and Better 1992) . Leaves and fruit extracts of this plant have displayed hypoglycemic, anti-inflammatory and analgesic effect in rats (Karumi and 
Materials and methods
Materials
Momordica balsamina seeds were procured from National seed stock and cultivated in Botanical garden, Punjabi University, India. Plant specimens were identified and confirmed by senior taxonomist. Gels for ion exchange and gel filtration chromatography were obtained from Sigma (St. Louis, US). All other chemicals were standard commercial products of analytical grade.
Purification of balsamin
Seeds (20 g) of M. balsamina were decorticated and ground by mortar and pestle to a powder form. The powder (20 g) was homogenized in 50 ml 150 mM NaCl. The mixture was stirred gently at 4°C. The slurry was filtered through muslin cloth and centrifuged at 10,0009g for 20 min at 4°C. The clear supernatant was collected and the proteins were precipitated by slow addition of solid ammonium sulfate (0-60%) with constant stirring using a magnetic stirrer at 4°C. After 8 h, the crude extract was centrifuged at 10,0009g for 10 min at 4°C. The supernatant was removed and resulting precipitate was dissolved in 15 ml of 10 mM phosphate buffer, pH 6.5 (Buffer A) and then dialyzed against same buffer. The protein solution was loaded onto a CM-Sepharose fast flow column (20 cm 9 1.5 cm), which was equilibrated with five column volumes of buffer A. The column was then washed with the same buffer at a flow rate of 1 ml min -1 until no protein eluted. Bound proteins were eluted with a linear gradient of 0-0.4 M NaCl in 10 mM phosphate buffer, pH 6.5 (Buffer B). The fractions that contained low-molecular mass proteins (based on SDS-PAGE analysis) were pooled. The fractions were concentrated by ultrafiltration using Amicon Ultra-15 10 kDa membrane. Concentrated fractions were loaded onto a superdex 75 column (10/300 GL, Amersham Biosciences Co., Piscataway, USA), prior equilibrated with (10 mM phosphate buffer, pH 6.5). The protein was eluted with 10 mM phosphate buffer, pH 6.5 at a flow rate of 0.5 ml min -1 . The eluted fractions that showed N-glycosidase activity were pooled, concentrated and stored at -20°C.
Protein concentrations of crude extract and fractionated sample at each step were calculated using the Bradford method (Bradford 1976 ).
SDS-PAGE
The molecular weight of balsamin was determined by SDS-PAGE performed according to the procedure of Laemmli (Laemmli 1970) , using a 12% resolving gel. After electrophoresis, the gel was stained with Coomassie brilliant blue R-250 (CBB). The molecular mass of the balsamin was determined by comparison with the protein markers; myosin (250 kDa), phosphorylase b (148 kDa), bovine serum albumin (66 kDa), glutamate dehydrogenase (64), alcohol dehydrogenase (50), carbonic anhydrase (36), myoglobin red (22) , lysozyme (16) and aprotinin (6) .
rRNA N-Glycosidase activity assay
The assay was carried out as previously described (Bagga et al. 2003; May et al. 1989 ). Rabbit reticulocyte lysate was taken as a source of ribosome. Rabbit reticulocyte lysate (50 ll) was treated with different concentration of balsamin (10, 20 and 50 lg ml -1 ) and incubated at 30°C for 30 min. The reaction was terminated by the addition of 10% SDS (w/v). Total rRNA was extracted with trizol reagent (Biorad). The RNA pellet was dissolved in 20 ll of water and divided into two parts. One part was treated with aniline acetate, pH 4.5, whereas the other part was left untreated. The aniline-treated and untreated samples were electrophoresed on 2% agarose gel. The gel was stained with ethidium bromide and the RNA was visualized on a UV-transilluminator.
Cell-free protein synthesis inhibition assay
The assay was performed according to the procedure described (Bagga et al. 2003; Sambrook et al. 1989 ). In the cell-free translation assay, 6 ll of the protein solution was incubated with rabbit reticulocyte lysate at 30°C for 60 min. The reaction was stopped by NaOH (250 ll, 1 N) containing H 2 O 2 (0.2%). After further incubation at 37°C for 10 min, the proteins were precipitated with trichloroacetic acid (15%) on ice for 30 min and harvesting was done on 26 mm glass fiber filters (Whatman). The dried filters were counted using a liquid scintillation counter. Saporin (a type I RIP) from Saponaria officinalis was used as a positive control (Bagga et al. 2003) .
N-terminal sequencing
The sequence of first 20 amino acids from N-terminal end was determined by Edman degradation method using an automated protein sequencer. Protein was subjected to SDS-PAGE using 12% separating gel. Blotting was performed at 350-400 mA for 35 min using polyvinyl fluoride membrane. After the transfer the membrane was stained and de-stained and then washed extensively with Milli-Q water. Protein blots were loaded on Blott TM cartridge (reaction chamber) of Applied Biosystems PROCISE 491 cLC Protein Sequencer and amino acid sequencing was conducted with protein sequencer.
Mass spectrometric analysis and protein identification
In gel trypsin digestion: The protein spots from coomassie stained gel were cut into 1 mm 3 pieces and transferred into a sterile micro centrifuge tube. In gel trypsin digestion was done as per the described protocol (Promega). The digested and extracted peptides were spotted onto MALDI sample plate and mixed with equal volume of a-cyano-4-hydroxylcinnamic acid matrix solution (10 mg/mL) in 0.1% TFA and 50% ACN. Peptide mass spectra were obtained using a MALDI-TOF/TOF 5800 mass spectrometer (ABSciex, CA) operating in reflectron mode over a window of m/z 700 to m/z 4,000. A combined MS peptide fingerprint and MS/MS peptide sequencing search was performed against the SwissProt 51.6 databases using the ProteinPilot software v4.0 (Applied Biosystems) via MASCOT search engine v2.2. Tryptic digestion with a maximum of one missed cleavage was considered. The search parameters allowed oxidation of methionine and carboxyamidomethylation of cysteine. The monoisotopic precursor ion tolerance was set to 100 ppm and the MS/MS ion tolerance to 0.4 Da. Protein identifications were accepted with a statistically significant probability based Mowse score (p B 0.01).
Sequence alignment
For multiple sequence alignment of balsamin RIP amino acid sequences, a search for sequence similarities was performed with BLAST program available on-line (http:// www.ncbi.nlm.nih.gov/BLAST). Sequence submitted was then aligned using Clustal W software in the default set up and alignment was analyzed.
CD spectroscopy
CD experiments were performed on Jasco J-815 spectropolarimeter. CD spectrum of the purified balsamin (1 mg ml -1 ) prepared in a sodium phosphate buffer (10 mM, pH 6.5) was measured in the far-UV range (200-240 nm) in 1 mm path length cuvettes. Analysis of the protein CD spectrum was performed using Spectra manager TM software (Jasco).
Results
Purification of balsamin
The proteins were precipitated by 60% ammonium sulfate saturation from M. balsamina seed extract. The protein precipitates were dialyzed against the buffer A and subjected to CM-Sepharose fast-flow column which was previously equilibrated with 10 mM phosphate buffer, pH 6.5 (Buffer A). Most of the protein was retained on the CM-Sepharose column; this indicates that proteins collected are mainly basic in nature. One major peak (BI) and two minor peaks (BII and BIII) were obtained using NaCl linear gradient (0.1 and 0.2 M) to elute bound proteins. The elution at 0.1 M NaCl resulted in one protein peak, peak BI, whereas 0.2 M NaCl gave rise to two peaks (BII and BIII) (Fig. 1) . Negligible amount of protein was eluted at higher salt concentrations. On SDS-PAGE peak BI contained balsamin (data not shown). The fractions from peak BI were pooled and after being desalted, further purification of those fractions was achieved using superdex 75 gelfiltration column. Four peaks (PI-PIV) were obtained (Fig. 2) . Table 1 summarizes the results of purification of balsamin indicating that 1 mg balsamin was purified. The purified fraction PII was subsequently found to possess rRNA N-glycosidase and cell-free protein synthesis inhibition activity. The purified balsamin from M. balsamina showed single band with a molecular weight corresponding to *28 kDa by 12% SDS-PAGE under denaturing conditions (Fig. 3) .
N-terminal sequencing
The first 12 amino acid residues from the N-terminal sequence of balsamin are DVSFTLSGADPS which showed homology with those of other type I RIPs in the Cucurbitaceae family recorded in GenBank ( Table 2 ). The sequence is similar to that of a-MMC (from Momordica charantia; 83% amino acid identity) , somewhat similar with TCS, TAP29 and trichokirin (from Trichosanthes kirilowii; 66 and 58% amino acid identity, respectively) (Shaw et al. 1991; Casellas et al. 1988 ). Balsamin has 50% similarity to several type-I RIPs purified from the Cucurbitaceae family such as b-MMC (from Momordica charantia) ; bryodin I (from Bryonia dioica) (Gawlak et al. 1997 ) and luffin a (from Luffa cylindrica) (Islam et al. 1990 ).
Protein identification
Balsamin, isolated from M. balsamina seed extract was further characterized by determining its primary structure. The protein was digested with trypsin and resulting peptides analyzed by mass spectrometry. Five peptides were identified out of which two peptides, REKVY NIPLLLPSVSGAGRY and RKITLPYSGNYERL, were unique to RIP from the seeds of Balsam apple (Momordica balsamina) thereby confirming the identification of the protein. The sequences of the peptide fragments were obtained with 99% confidence. The calculated molecular mass obtained from SDS-PAGE was 28 kDa. The theoretical molecular mass obtained by mass spectrometry protein identification methods was 29.1 kDa. However, both methods identified the protein to be ribosomal-inactivating protein (Table 3 ). The confidence/accuracy levels of peptide identification and sequences identified and the molecular masses of the fragments are listed (see supplementary information Table S1 ). Figure 4a shows the alignment of balsamin amino acid sequences with other type I RIPs. The amino acid sequences of balsamin were used to find homology with other type I RIPs deposited in GenBank. A BLAST search was performed to trace the possible similarity between the amino acid sequences of balsamin and other RIP sequences. Further analysis showed that balsamin has the highest similarity with a-MMC from M. charantia than to any other type I RIPs. Sequence from mass spectrometric analysis has 78% sequence identity with a-MMC, whereas, it has less identity with b-luffin, bryodin I, trichomislin, trichobakin and trichosanthin. From multiple alignment (as shown in Fig. 4a ), a phylogenetic analysis of balsamin was carried out by comparing its amino acid sequence with those of known RIPs from other plants. Balsamin and a-MMC are located on the same branch and other RIPs originated from this branch. The phylogenetic tree shows the close relationship of balsamin with a-MMC and its distances from other RIPs. Trichomislin from T. kirilowii is more closely related to bryodin from Bryonia dioica, trichosanthin and trichobakin from T. kirilowii than balsamin (Fig. 4b) .
RNA N-glycosidase activity It has been demonstrated that RIPs are RNA N-glycosidases and they catalytically cleave the N-glycosidic bond specific to adenine residue at position 4324 in rat 28S rRNA. After further treatment with acidic aniline, the phosphodiester bond splits at the depurination site, and a specific RNA Cell free protein synthesis
Balsamin was tested in a rabbit reticulocyte lysate translation system to investigate whether it inhibits protein synthesis in a cell-free environment. The lysate was treated with different concentrations of sap-6 and balsamin. Balsamin from M. balsamina and saporin-6 (sap-6, a positive control) from Saponaria officinalis both inhibited protein synthesis in the rabbit reticulocyte lysate system. The lysate was treated with different concentrations of sap-6 and balsamin. Balsamin effectively inhibited protein synthesis with an IC 50 90 ng ml -1 (Fig. 6 ). In this experiment balsamin appeared to be less toxic than the saporin-6 which has an IC 50 3 ng ml -1 .
Secondary structure determination of balsamin
The far-UV CD spectrum suggests the presence of both a-helical and b-sheet conformations. The CD spectrum used to calculate secondary structures of balsamin by using spectra manager software ( Figure 7) . Balsamin contains 23.5% helix, 24.6% b-strand, 20% turn and 31.9% random coil (data not shown). Balsamin cleaves a single N-glycosidic bond between base and ribose at position A4324 in 28S rRNA, similar to the other type-I RIPs. Balsamin displayed N-glycosidase activity by producing the Endo fragment and also cell-free protein synthesis inhibitory activity which are similar to other RIPs (Bagga et al. 2003) . The action of balsamin on rRNA in the presence and absence of aniline is similar to that of other RIPs (Barbieri et al. 1993 ). Balsamin possesses a potent cell-free translation inhibitory activity (IC 50 = 90 ng ml -1 ), which is a property for type I RIPs. It adsorbed to CM-Sepharose column, similar to the chromatographic behavior of other RIPs (like a-MMC, b-MMC and MAP30) from M. charantia ; LeeHuang et al. 1990 ). N-terminal sequence of balsamin shares 83% similarity with a-MMC from Momordica sp. Homology comparison of N-terminal amino acid sequence suggested a high similarity of balsamin to already known RIPs. Balsamin matched with a-MMC according to mass spectrometry results. Alignment of the balsamin sequence shows that some residues are conserved between other RIPs like luffin b, bryodin, trichosanthin, trichomislin and trichobakin. Balsamin secondary structure contains helix (23.5%), b-strand (24.6%), turn (20%) and random coil (31.9%). Phylogenetic relationship showed that balsamin and alpha MMC can be grouped together and other RIPs originated from this branch. The tree showed close relationship of balsamin with a-MMC than other RIPs. Alpha MMC has abortifacient (Law et al. 1984 ), anti-tumor, immune response suppressor ) and anti-HIV-1 ), deoxyribonuclease ) and ribonuclease activities. Thus, balsamin also appears to be active as alpha MMC; it remains to be elucidated whether the balsamin is equipotent in other biological activities. These results may provide significant insights into the relationship between the various biological and enzymatic activities observed. It is noteworthy that some of the plants containing RIPs are eaten raw by humans (e.g., spinach, pumpkin) which mean that materials containing those levels of RIPs are not harmful. Pharmaceutical-grade trichosanthin has been used for many years in China as an abortifacient and as an anticancer agent for choriocarcinoma (Lau et al. 1980 ). Phase I trial has been done with subcutaneous application of aviscumin in patients with progressive malignant tumors. Aviscumin induced the secretion of IL-1b and IFN-c in plasma and stimulation of T-cells that mediated an in vivo anti-tumor T cell response (Bergman et al. 2008 ). Several health organizations around the world have recommended an increase in the intake of plant-derived food in order to improve human health status (Espin et al. 2007 ). Particularly the proteins from bitter melon are suitable for specific products (where the native form is needed) since they can resist higher temperature during processing. All the essential amino acids of bitter melon proteins with the exception of Threonine met the minimum requirements for preschool children by FAO/WHO/UNU (Horax et al. 2010 ). Thus, RIPs expressed in vegetables like Momordica sp. may be promoted as ''functional ingredient'' in a food system since it does not possess any toxic effect for humans and are useful as they possess anti-viral activity. Thus efforts are being made in many laboratories to purify RIPs from plants and check its activity against HIV and various tumors, which may allow their usage as potential nutraceutical.
In conclusion, balsamin, the basic protein isolated from Momordica balsamina has the properties of type I RIP as it (i) is a single-chain protein with a molecular mass of approximately 28 kDa; (ii) possesses enzymatic N-glycosidase activity on rabbit reticulocyte rRNA and (iii) releases Endo fragment after aniline treatment (Fig. 2) . Furthermore, balsamin inhibits protein synthesis in cellfree system with IC 50 value of 90 ng ml -1 . Based on its above-mentioned activities, balsamin may be promoted as a nutraceutical. 
Introduction
Ribosome-inactivating proteins (RIPs) were first discovered in the castor oil plant, Ricinus communis, following the isolation and characterization of ricin [1] . However, RIPs are synthesized and widely distributed among plant genera, and have so far been found in more than 50 different species from 14 families, including the Cucurbitaceae, Euphorbiaceae, Poaceae and Caryophyllales [2] . RIPs function by irreversibly inhibiting protein synthesis through the removal of one or more adenine residues from ribosomal RNA (rRNA). RIPs are traditionally categorized into two types, referred to simply as type I and type II. Type I RIPs are single-chain proteins with a molecular weight of approximately 30 kDa, whereas type II RIPs, with an approximate molecular weight of 56-65 kDa, consist of an enzymatically active A-chain and a slightly larger B chain (a lectin subunit) with specificity for sugars exhibiting galactose-like structures [3] . Both types of RIP are localized either to plant leaves, seeds or roots. However, single-chain type I RIPs are significantly more common than their type II relatives [2] . Interestingly, type I RIPs, such as saporin, pokeweed antiviral protein and trichosanthin (TCS), are less cytotoxic than their type II counterparts, such as abrin and ricin. However, there are some type II RIPs that are non-toxic in nature [4] . The attenuated cytotoxicity of type I RIPs is the result of the absence of the cell-binding B chain [2] . Despite this cytotoxicity, type I RIPs are able to enter mammalian cells to some extent, but the precise mechanism of entry is still poorly understood. In addition to the two classic types of RIPs, a 60-kDa RIP, referred to as JIP60, has been identified from barley (Hordeum vulgare). JIP60 comprises an amino-terminal domain resembling type I RIPs linked to an unrelated carboxyl-terminal domain with unknown function. Thus, it is referred to as a type III RIP [5] . RIPs are ubiquitous in the plant kingdom, and abundantly present in some plant families, as mentioned above. Their role in nature is not yet completely understood, which leaves room for potential future developments. Based on existing knowledge regarding their structure, function and biological activities, RIPs from plants have potentially useful applications in agriculture and medicine. They have both antiviral and antitumor activities, which have been exploited in the preparation of immunotoxins (via antibody conjugates) by rendering the activities specifically toxic to the targeted cell [6] .
Current biotechnological research into RIPs is targeted at better understanding and subsequent improvement of the cell entry mechanism, increasing specificity, reducing RIP antigenicity, prolonging their plasma half-life and understanding their role in apoptosis. These are important factors that strongly limit the application of RIPs as therapeutic agents, and are among the most active areas in current biomedical research. Accordingly, in this review, we focus on studies that have characterized the diversity, mechanism of cell entry and stability of RIPs from several plant families. We also discuss the potential biomedical applications of RIPs, including the development of a novel class of herbal-based therapeutics.
Types of RIP
Naturally occurring RIPs are found in some plant families. The highest levels of RIPs found in seeds of species from the Caryophyllaceae, Cucurbitaceae, Euphorbiaceae and Phytolaccaceae. The type I and II RIPs that have been sourced from plants are detailed in Table 1 [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] .
Functions of RIPs Glycosidase activity
Any protein exhibiting a glycosidase activity can be categorized as an RIP. The A ricin A-chain removes a single adenine residue from position 4324 in the 28S rRNA of rat liver ribosomes, defining RIPs as ribosome-specific N-glycosidases [25] . Depurination occurs on a highly conserved stem-loop structure found in the large RNA of all ribosomes. Ricin recognizes a highly conserved region in the large 28S rRNA and cleaves a specific N-glycosidic bond between an adenine and the nucleotide on the rRNA. The depurinated adenine is in the highly conserved sequence, GAGA, which has been shown to be important for the interaction with the ribosome-elongation factor (Fig. 1) . After the removal of adenine, the deadenylated site becomes unstable and a b-elimination reaction can occur after the RNA is treated with acidic aniline, whereby the 3 0 end of the rRNA is cleaved and can be detected by electrophoresis. This site is usually depicted as being present in a single-stranded loop, called the sarcin-ricin loop. It is located in domain VII, some 400 nucleotides from the 3 0 end of the rRNA [1, 3, 6] . This particular site-specific RNA N-glycosidase activity is a common property of all type I and type II RIPs identified so far. RIPs from Momordica charantia depurinate intact ribosomes in the same manner as the ricin A-chain. As for the A-chain of ricin, Momorcharin from Momordica charantia (a-and b-MMC) also deactivates eukaryotic ribosomes using a similar catalytic mechanism [26] . Another study showed that the action of a-and b-MMC on rRNA was very specific, with Momorcharins (MMCs) acting only on the 28S rRNA, but not on 18S, 5.8S and 5S rRNA, resulting in the release of a RNA fragment known as 'Endo's fragment' upon acidic aniline treatment of isolated rRNA. The N-glycosidase activity of the MMCs is not affected by a change in pH from 6.5 to 9.0, but enzyme activity increases with the K + concentration. By contrast, the enzyme activity of b-MMC fluctuates slightly with an increasing concentration of NH4 + ions, whereas a significant inhibitory effect is observed with increasing Mn 2+ concentration [6] .
g-Momorcharin also exhibits RNA N-glycosidase activity on ribosomes isolated from rat liver in a dose-dependent manner. To determine the action site of g-momorcharin on 28S rRNA, the sequence of 5 0 -terminal nucleotides of the RNA fragment produced by g-momorcharin and/or aniline treatment was analyzed. By comparing this nucleotide sequence with that produced by ricin, Drug Discovery Today Volume 17, Numbers 13/14 July 2012 REVIEWS www.drugdiscoverytoday.com 775
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it was shown that g-momorcharin acts on the same active site of 28S rRNA from rat liver ribosomes [6, 26] . Catalytic A-chain of ricin (RAT), saporin-S6 (from Saponaria officinalis) and RIP from Mirabilis expansa (ME) (from Mirabilis spp.) depurinate fungal ribosomes isolated from Rhizoctonia solani, Alternaria solani, Trichoderma reesei and Candida albicans. RAT showed the strongest toxicity against the three fungal ribosomes except for that from C. albicans. It also showed enzymatic activity against R. solani and T. reesei at a concentration of 1 ng ml
À1
. The enzymatic activities of saporin-S6 and ME were approximately five times and 50 times lower against R. solani than were those of RAT, respectively. The enzymatic activity of ME against A. solani ribosomes was lower than that of the other two RIPs. RAT was shown to exhibit less enzymatic activity against C. albicans ribosomes than against other fungal ribosomes. ME showed no depurination activity towards T. reesei and C. albicans ribosomes at a concentration up to 100 ng ml À1 [27] . Beetin (BE) isolated from Beta vulgaris depurinated both rabbit and Vicia sativa ribosomes, and released RNA fragments upon acid aniline treatment [28] .
Inhibition of protein synthesis
RIPs from M. charantia were found to be potent inhibitors of protein synthesis in a cell-free system. Lectins were first detected in M. charantia because of their ability to inhibit protein synthesis 
FIGURE 1
Mechanism of action of ribosome-inactivating proteins (RIPs). A specific N-glycosidase activity cleaves adenine (A 4324 ), which is located in the sarcin-ricin loop of the ribosomal RNA of the large subunit. The reaction product of the RNA N-glycosidase (deadenylated rRNA) acts as a substrate for ribosomal RNA purinic site-specific lyase (RALyase), which cleaves the phosphodiester bond at the 3 0 -end. The reaction products are a short (4325-4785) 3 0 -end fragment and a long (1-4324) 5 0 -fragment with a free 3 0 -hydroxyl terminus [2] [3] [4] [5] [6] .
in Ehrlich ascites cells [6, 14, 29] . Lectin from M. charantia is the second example of a non-toxic lectin, inhibiting protein synthesis in vitro after R. communis agglutinin [1] . As for lectins, a-and bMMCs also inhibit protein synthesis in rabbit reticulocyte cell-free lysates. The potencies (ID 50 ) of the cell-free protein synthesis inhibitory activity of a-MMC and b-MMC are reported to be as low as 0.12 nM and 0.11 nM, respectively [6] . Regarding lectins and MMCs, MAP30 exhibits a dose-dependent inhibition of a cell-free translation system. Eukaryotic translation inhibition by MAP30 was assayed in a rabbit reticulocyte lysate system and the effect on protein biosynthesis expressed as the incorporation of [ 3 H]-labeled leucine into a trichloroacetic acid (TCA) insoluble product. MAP30 exhibited cell-free translation inhibition in a dose-dependent manner with an ID 50 of 3.3 nM [6, 30] . Ribosome inactivation activity of recombinant MAP30 (rec-MAP30) was also measured by in vitro translation of the globin message in a rabbit reticulocyte lysate system. Rec-MAP30 exhibited a similar ID 50 (3.3 nm) to that observed for natural MAP30 (nMAP30). Interestingly, MAP30 could not enter uninfected (normal) cells and was incapable of activating cellular ribosomes and inhibiting cellular protein synthesis in those cells [10] .
g-Momorcharin also inhibits protein synthesis in a dose-dependent manner in rabbit reticulocyte lysates with an ID 50 of 55 nM. Compared with a-MMC, b-MMC and MAP30, the higher ID 50 value might be attributed to the small molecular weight of this RIP [6, 26] . However, the potency of d-momorcharin is similar to that of a-and b-MMC with an IC 50 of 0.15 nM. Contrastingly, emomorcharin and charantin exhibit much weaker inhibition of cell-free protein synthesis with ID 50 values of 170 nM [6] and 400 nM [31] , respectively.
Musarmins (MU 1, 2 and 3) isoforms from Muscari armeniacum display inhibitory activity on several cell-free systems from mammals and plants. Three isoforms of MU showed strong inhibitory activity on rabbit reticulocyte system. MU 1, 2 and 3 had IC 50 values of 7, 9.5 and 4 ng ml À1 , respectively. In rat liver, IC 50 values 79, 95 and 101 ng ml À1 were recorded for MU 1, 2 and 3, respectively. High concentrations of MU 1, 2 and 3 did not result in protein synthesis activity against plant-derived cell-free systems [32] . Tobacco RIP (TRIP), a single-chain RIP isolated from Nicotiana tabacum leaves, inhibited translation in wheat germ and rabbit reticulocyte systems. It also inhibited the wheat germ translation system more efficiently than it did the rabbit reticulocyte system. In addition, TRIP inhibited protein synthesis in a wheat germ translation system at a lower concentration and with an IC 50 of 30 ng ml À1 compared with 100 ng ml À1 for the rabbit reticulocyte system [33] . BE inhibited protein synthesis more efficiently in rabbit reticulocyte lysates compared with in rat liver, V. sativa L., and Triticum aestivum IC 50 values for rabbit reticulocyte lysates, rat liver, V. sativa L., and T. aestivum L. cell-free systems were 1.15, 68, 617 and 1318 ng ml
À1
, respectively [28] .
Structure-function relationship of type I RIPs
The three-dimensional structure of bouganin (from Bougainvillea spectabilis) and lychnin (from Lychnis chalcedonica) have been elucidated, along with their activities together with those of dianthin 30, PAP-R, RTA, saporin-S6 and momordin I. Relative to other RIPs, Saporin-S6 has the highest protein synthesis inhibitory activity, and efficiently deadenylates polynucleotides from rat ribosomes, poly(A) and herring sperm DNA (hsDNA). Lychnin showed little increase in protein synthesis inhibitory activity compared with bouganin. Deadenylation of poly(A) was inefficient for both lychnin and bouganin. Structure analysis of saporin-S6 revealed the presence of several exposed arginine and lysines residues surrounding the active site cleft. In lychnin, the electrostatic surface potential does not favor adenine removal. Bouganin showed some negative potential at the active site, but the negative charge of some surrounding residues prevented the enzyme-substrate interaction [6, 9, 14, 26, 49] .
Antitumor activity
The RIPs from many plants have shown antitumor activity both in vitro and in vivo [34] [35] [36] . An overview of RIPs with antitumor activity is provided in Table 2 . MAP30 exhibits antitumor activity against certain human tumor cell lines originating from renal, non-small cell lung and breast cancer tumors. Antitumor activity of rec-MAP30 has also been studied in several human tumor cell lines, such as brain glioblastoma, breast carcinoma, epidermoid carcinoma, liver hepatoma, melanoma, myeloma, neuroblastoma
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and prostate carcinoma [37, 38] . The antitumor activity of rec-MAP30 and nMAP30 was identical with respect to their sensitivity to particular tumor types. The most sensitive tumor cell lines were breast, central nervous system, melanoma and myeloma tumors with EC 50 values of 0.21-0.38 nM. Prostate and epidermoid carcinomas were less responsive, with ID 50 values of 3.42 and 1.88 nM, respectively [37] . Dexamethasone is used to treat cancers, such as Hodgkin's disease, non-Hodgkin's myeloma and lymphocytic leukemia, through inhibition of nuclear factor (NF)-kB activity [39] . Dexamethasone (1 mM) treatment of HepG2 cells does not generate an antiproliferation effect, but efficiently inhibits TCS-induced degradation of a cytoplasmic inhibiting protein (IkB-a protein) and enhanced TCS-induced apoptotic death in HepG2 cells. Dexamethasone might also inhibit dissociation of NF-kB in the cytoplasm and promote the transcription of the gene encoding IkB-a, resulting in suppression of NF-kB activation and enhanced TCSinduced antitumor effects [40] .
In addition, recombinant luffin from Luffa cylindrica displays in vitro cytotoxicity against various tumor cell lines. Recombinant luffin inhibited proliferation of JEG-3 (human placental choriocarcinoma), HepG2 (human hepatoma) and MCF-7 (human breast cancer) cell lines in a dose-and time-dependent manner [41] . Tianhua (TH-R), identified from Trichosanthes kirilowii, was recently found to inhibit the growth of the human lung cancer A549 cell line by arresting the G0/G1 phase of the cell cycle in a dose-and time-dependent manner and inducing apoptosis [42] .
Fibroblast growth factor-inducible 14 (Fn14), related to the tumor necrosis factor (TNF) receptor superfamily, has been shown to regulate a variety of cellular functions, including cell survival, cell growth, angiogenesis and inflammation. Although Fn14 is expressed at relatively low levels in normal tissues, local expression increases dramatically in injured and diseased tissue [43] . Recombinant gelonin (rGel), a type I RIP, conjugated to an anti-Fn14 monoclonal antibody (ITEM-4) was highly cytotoxic to a FN14-expressing tumor cell line. Upon administration of an immunoconjugate, ITEM-4-rGel enhanced long-term tumor growth suppression in nude mice bearing a T-24 human bladder cancer cell xenograft [44] .
Antiviral activity
RIPs from M. charantia have broad-spectrum antiviral properties against different viruses through inhibition of viral protein synthesis in the infected cell. This, coupled with the ability of RIPs to inactivate eukaryotic ribosomes in vitro, suggests that the mechanism of antiviral action involves inactivation of host ribosomes in virus-infected cells [6] . Similarly, pokeweed antiviral protein (PAP) from Phytolacca americana exhibits antiviral activity against several viruses and also inhibits the production of the human T-cell leukemia virus I (HTLV-1). HTLV-1 is a delta retrovirus that is a causative agent of adult T-cell leukemia. It has also been associated with myelopathy and/or tropical spastic paraparesis. Currently, there is no effective antiretroviral treatment available to restrict the development of diseases associated with this virus. PAP-depurinated nucleotides within the gag open reading frame suppress the synthesis of viral proteins by decreasing the translational efficiency of HTLV-1 gag/pol mRNA [36] . Viral mRNA reduction resulting from a decrease in the viral transactivator protein, Tax, leads to feedback inhibition of transcription from the viral promoter. PAP diminishes virus production by suppressing the expression of the gene encoding HTLV-1 gene at both the translational and transcriptional levels [6] .
TCS in Phase I and/or II clinical trials elicits a moderate increase in circulating CD4+ T cells and a significant decrease in p24 levels in patients with AIDS failing treatment with antiretroviral drugs, such as zidovudine [45] . TCS recognizes HIV-1 through viral envelope interactions. The viral envelope is significantly different to host cell membranes and has a rich lipid raft content and a high level of sphingolipid and cholesterol [46] . Exogenous TCS taken up by HIV-1-infected cells is associated with the lipid rafts on HIV-1 budding sites, where TCS-enriched virions are generated. TCS exploits the sorting strategy to eradicate both budding and prevent virus dissemination [47] .
Studies further show that the MAP30 RIP inhibits production of the hepatitis B virus (HBV). The exposure of HepG cells to MAP30 results in inhibition of HBV DNA replication and HBsAg secretion. More specifically, MAP30 is shown to inhibit the expression of the HBV antigen, decrease viral DNA replication, downregulate replicative intermediates and reduce cDNA synthesis. High doses of MAP30 are also effective in suppressing viral replication by altering the kinetics of replicative DNA intermediates, whereas lower doses of MAP30 inhibit the expression of HBsAg and HBeAg. Thus, MAP30 inhibits the production of HBV in a dose-and timedependent manner [48] . Luffin P1, the smallest RIP from the seeds of L. cylindrica, has been observed to have a potent effect on HIV replication. HIV viral replication requires assembly of a ribonucleoprotein (RNP), which comprises a Rev protein homo-oligomer and Rev response element (RRE) RNA to mediate nuclear export of unspliced viral mRNAs [46] . Rev binds to one specific site in the RRE using a 17-amino acid a-helical arginine-rich motif (ARM) for interaction with RRE. The a-helical structure of Rev ARM is important for RRE binding and the C-terminus of luffin P1 is similar to the Rev ARM. Therefore, luffin P1 might inhibit HIV-1 replication by interacting with the RRE [49] .
Recent studies report the construction of several maize variants by the addition of HIV-1 protease recognition sequences to the internal inactivation region. Two maize RIP variants activated by recombinant HIV-1-infected cells inhibited viral replication in human T-lymphocytes and enhanced N-glycosidase activity. The first and last ten amino acids of Pro-RIP replaced with an MA/CA site and a Pro-RIP-MA/CA construct were cleaved completely by HIV-1 protease. Eleven amino acids were derived from the HIV-1 TAT-protein and fused with N termini of Pro-RIP and MOD to generate TAT-Pro and TAT-MOD variants. The substitution of HIV-1 protease recognition sequences (the p2/NC site and MA/CA site) generated two TAT-fused maize RIP variants: TAT-Pro-HIV-p2/NC and TAT-Pro-HIV-MA/CA. The TAT-Pro and TAT-MOD maize-RIP variant exhibited dose-dependent inhibition of HIV replication in HIV-1 IIIB and an HIV-1 protease inhibitor-resistant virus strain. TAT-Pro had a weaker inhibiting effect on p24 antigen production and syncytium formation compared with TAT-Pro-HIV-MA/CA, TAT-Pro-HIV-p2/NC and TAT-MOD [50] .
Mechanism of entry
RIPs enter the cell by first binding to cell surface receptors, then crossing the cell wall via endocytosis and finally entering the cytosol via translocation from intracellular endocytic compartments. This occurs after retrograde transport through the Golgi apparatus to the endoplasmic reticulum (ER) [2] . In the ER, the catalytic moieties exploit the ER-associated degradation (ERAD) pathway to reach their cytosolic targets. Most of the observations concern type II RIPs and suggest that more than one mechanism of internalization is involved. The cell-RIP interaction shows common features, including: (i) only some of the toxin molecules taken up by the cells are transferred into the cytosol and so reach their target; (ii) inhibition of protein synthesis can only be detected in cells at least 30 min after it occurred; and (iii) a single RIP molecule might be sufficient to induce cell death [5] .
Internalization of type II RIPs
Ricin (a type II RIP) has evolved a mechanism for efficiently entering mammalian cells (Fig. 2) . Other type II RIPs from plants are structurally and functionally equivalent to ricin, and it is assumed that their mechanism for entering target cells would be similar.
Binding to the cell surface
The first step in the cell-RIP interaction consists of RIP binding to membrane receptor sites through b-1,4 linked galactose residues, which are widely present on mammalian cell surface glycoproteins and glycolipids. The A and B-chains of ricin have mannose-containing oligosaccharide groups, which are mainly responsible for the uptake and toxicity of the toxin in rat liver kupffer and sinusoidal cells (non-parenchymal cells) [1] . However, ricin uptake by these cells is completely abolished in the presence of both galactose and mannan [51] . The binding of lanceolin and stenodactylin to cells was assessed by association with glycosylated molecules on the cell membrane through their lectin-B-chains. The presence of galactose inhibits the binding of the RIP through the lectin-B chain [52] .
Endocytic uptake
Type II RIPs do not directly cross the plasma membrane, but enter the cytosol via the endocytic pathway. Ricin binds to a variety of cell surface components, where it uses different endocytic mechanisms to enter cells. Receptor-mediated endocytosis usually occurs by way of clathrin-coated pits, which are specialized depressions on the cell surface. The binding and internalization of ricin by Vero cells was first observed to use clathrin-dependent endocytosis [53] . Mannose-containing RIPs use this method of endocytosis, after being bound to mannose receptors localized in coated pits [1, 6] . Unlike other cytotoxic Type II RIPs, lanceolin 
FIGURE 2
Pathway of ricin, a ribosome-inactivating protein (RIP), uptake by a cell and the putative mechanism whereby the toxic activity of the ricin A-chain in the cytoplasm results in cell death. Modified from [56, 68] .
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and stenodactylin are internalized by mechanisms independent of clathrin-coated pits [52] .
Endocytosis
The endocytic pathway comprises early and late endosomes and lysosomes. Endocytosis involves cell surface invagination of both coated and non-coated pits, leading to the formation of endosomal vacuoles. Ricin initially enters cells endocytically and is delivered to early endosomes, from where most of it is either recycled back to the cell surface or delivered via late endosomes to lysosomes, where it is proteolytically degraded. Resistance to ricin is observed when endosome-to-Golgi transport is blocked by low temperature [54] . Treating cells with ionophore monensin or Brefeldin A (BFA) compounds, which influence the Golgi morphology and function, confers resistance to Type II RIP. This suggests that the Golgi complex is required for type II RIP intoxication. Internalization can be visualized within the trans-Golgi network (TGN). Ricin binds to a variety of different surface molecules and follows various intracellular routes, one or more of which enable the toxin to be transferred into the cytosol [53] . The intracellular trafficking of lanceolin and stenodactylin is similar to that of ricin. The addition of BFA resulted in substantial protection of cells against protein synthesis induced by lanceolin and stenodactylin [52] .
Transfer from Golgi apparatus to the endoplasmic reticulum
Toxins from TGN undergo retrograde transport through the Golgi stack to reach the ER lumen. Retrograde transport of ricin from the Golgi-to-ER step involves the movement via coatomer protein I (COP-I)-coated vesicles [55] . Transient expression of trans-dominant negative GTAases that regulate vesicle transport steps in the early secretory pathway partially protected cells against ricin, whereas the addition of an ER-retrieval sequence (KDEL) to the C-terminus of RTA increased the cytotoxicity of free RTA [51] and reconstituted holotoxin [1] . The RTA-KDEL interacts with Golgito-ER cycling KDEL receptors. The direct evidence for Golgi-to-ER transport of ricin was shown by the BFA-sensitive uptake and core glycosylation of a non-glycosylated toxin. Post-translational core glycosylation of an endocytosed protein provides evidence for the retrograde transport of ricin from the cell surface to the ER, where the oligosaccharyl transferase responsible for the core glycosylation is located [51, 55] .
Membrane translocation
Ricin and other type II RIPs are non-pore forming toxins, which undergo retrograde vesicular transport to the ER and into the cytosol via translocation machineries [51] . Misfolded proteins do not accumulate in the ER lumen and RTA is expelled from the ER to the cytosol. Orphan subunits that fail to become incorporated into the appropriate multimeric complexes, and aberrant proteins that are unable to assume their biologically active conformations, are detected at this stage and eliminated by proteolytic degradation. Degradation of protein in the cytosol is carried out by proteasomes. It is recognized that such proteins are exposed to the ER and proteolytically degraded in the cytosol [55] , a pathway known as ER-associated protein degradation (ERAD) (Fig. 2) . In the ER lumen, RTA unfolding occurs owing to its interaction with the lipid membrane; unfolded RTA then acts as an ERAD candidate, leading to its export into the cytosol [56] . Lanceolin and stenodactylin associated with cells are released into the supernatant during cellular processing and exocytosis. Unlike other type II RIPs, the percentage of non-degraded lanceolin and stenodactylin is high. Stenodactylin showed greater uptake, exocytosis and re-uptake of non-degraded RIPs [52] .
Internalization of type I RIPs
Type I RIPs lack the lectin B-chain that facilitates entry and accounts for the extreme toxicity of type II RIPs. Type I RIPs are less toxic than type II RIPs, but become highly toxic if they are introduced into cells by linkage to an appropriate carrier that is capable of binding to cells. Gelonin, when conjugated with concanavalin A, demonstrates more toxicity to cells than does free gelonin [5] .
Intracellular movements of saporin rely on Golgi-mediated retrograde transport to reach their retrotranslocation site. Cell surface binding of saporin is mediated by members of the low density lipid (LDL)-related family receptors and LRP-minus MEF cells, which showed a ten-times decrease in saporin sensitivity and mediated the internalization of the amino-terminal fragment (ATF)-saporin chimera through clathrin-coated pits. The Golgi complex is not a major intracellular compartment for productive trafficking of saporin compared with Vero or HeLa cells treated with BFA. However, saporin does not appear to have putative translocation domains and the cytotoxic activity of the ATFsaporin chimera is slightly increased both by chloroquine or bafilomycin A1 treatments, suggesting its passage through a putative proteolytic compartment. Saporin toxicity is not affected by treatment with BFA or chloroquine, indicating that saporin follows a Golgi-independent pathway to the cytosol and requires a low pH for membrane translocation [57] .
TCS (a type-I RIP) interacts with the negatively charged phospholipid-containing monolayer under acidic conditions through hydrophobic interactions. The acidic microenvironment of the membrane changes the charges on some residues, resulting in breakage of salt bridges and charge-charge repulsion, which partially denatures TCS to a 'molten globular state' and finally leads to its membrane insertion [26] . Recent studies suggest that receptorrelated protein 1 (LRP1) is an essential receptor for TCS endocytosis by JAR and BeWo choriocarcinoma cell lines that express LRP1. This might be one of the mechanisms underlying the application of TCS in the treatment of trophoblastic cancer. Choriocarcinoma cell lines significantly bind and internalize TCS that express LRP1. By contrast, HeLa cell lines have no detectable TCS binding and endocytosis. Thus, it is suggested that HeLa cells have no detectable LRP1 and an inability to bind TCS [58] .
Plasma half-life of RIPs
In pharmacoproteomics and structural genomics, many newly identified bioactive proteins are generally unstable in vivo. To overcome this problem, RIPs need conjugation to water-soluble polymers such as polyethylene glycol (PEG). PEG is a non-toxic, nonimmunogenic, non-antigenic, water soluble and US Food and Drug Administration (FDA)-approved polymer. Covalent coupling of PEG to proteins is an effective way of prolonging plasma half-life and reducing immunogenicity. This polymer has been used extensively for the modification of proteins and PEGylation conducted nonspecifically through the e-NH 4 site of lysine residue [59] . Usually, there is more than one residue (e.g. lysine) in a protein and its
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PEGylation produces different products with variation in their structure and activity. PEGylation of proteins usually results in masking some surface sites, increasing the molecular size and enhancing steric hindrance. Therefore, attachment of PEG to proteins decreases their immunogenicity, improves the plasma half-life and stabilizes against proteolytic cleavage [60] . TCS was the first RIP found to have anti-HIV activity in vitro. It has limited clinical applications because of its major adverse effects, short plasma half-life, immunogenicity and neurotoxicity. TCS administration elicited production of specific antibodies in vivo and its re-administration resulted in a severe anaphylactic reaction leading to death. TCS plasma half-life range is 8.4-12.7 min in vivo. This range requires frequent administration to maintain an effective therapeutic concentration in the blood [45] . PEGylation is shown to reduce immunogenicity and prolong the circulating half-life of proteins. Specific antibodies neutralize some TCS, speed up its plasma clearance and rapidly clear glomerular filtration, which facilitates its loss via urine, all of which result in the short plasma half-life of TCS.
Further studies show that TCS has three antigenic sites: Ser (S7), Lys-173 (K173) and GlN-219 (Q219). These sites are mutated to a cysteine residue, namely S7C, K173C and Q19C. The sulfhydryl group of the newly created solitary cysteine residue of S7C, K173C and Q219C is used for PEG 20K attachment. PEG masks antigenic sites to prevent specific antibodies binding and so reduces antigenicity and improves plasma half-life; however, in vitro RIP activity is not affected. The anti-HIV activity of PEGylated TCS is retained and the longer plasma half-life can usually compensate for the reduction in activity [61] .
On further investigation of PEGylated TCS, two antigenic sites of TCS; YFF81-83 and KR173-174, mutated by site-directed mutagenesis and then PEG-maleimide, were coupled with the newly created cysteine residue by site-directed PEGylation. The mean residence time (MRT) of the PEGylated TCS mutants increased 4.5-6-fold and the high-plasma clearance (C1 p ) was reduced by approximately 50% compared with natural TCS (nTCS). The increase in molecular size of the PEGylated TCS conjugate led to reduced renal clearance, and resistance of PEGylated proteins to proteolysis contributed to the prolonged plasma half-life [62] .
RIPs from bitter melon seeds were subjected to PEG modifications. Chemical modification of RIP with 20-kDa (mPEG) 2 -Lys-NHS was performed to reduce immunogenicity by increasing the plasma half-life for in vivo application. The inhibitory activity of both non-PEGylated and PEGylated RIP against cancer cells, as measured by the caspase 3-assay (apoptotic pathway), is much stronger than against normal cells. The antigenicity of PEGylated RIP is reduced and plasma half-life in vivo increased [63] .
Antigenicity of RIPs
The immunogenicity of RIPs imposes limitations on the use of these proteins as therapeutic agents. Reduction of the antigenicity of RIPs has been attempted using various approaches, including chemical modification of the proteins, such as site-specific coupling to dextran and PEG, and protein engineering. It has been observed that proteins modified by PEG are less immunogenic.
Repeated use of a-MMC can elicit an antigenic response that might neutralize its biological activity. Modification of a-MMC was undertaken to make it less antigenic while maintaining its biological activities. The three epitopic regions were determined from the three-dimensional structure of a-MMC that included the largest epitopic region from residues 71 to 136; the other two regions were from residues 1 to 14 and 195 to 222. Residues 71-136 are in close proximity to the active site and antibody binding onto these residues blocked the active site. On increasing the concentration of a-MMC, protein synthesis was inhibited; in turn, the presence of monoclonal antibody A1 blocked this inhibition [5, 6, 14] .
TCS from T. kirilowii when administered to patients with AIDS induced mild to severe anaphylactic responses and neurological disorders, including myalgia, nausea, diarrhea and flu-like symptoms [45] . To reduce the adverse effects of TCS as a drug, the Cterminal domain, which contains putative antigenic sites, was systematically deleted. The C-terminus of TCS does not contain any active sites, thus deletion of the domain results in a less antigenic variant of TCS that retains its biological activities and exhibits antigenicity. In one variant of TCS, C7, the last seven amino acid residues at the C-terminus (residues 241-247) are deleted, leading to decreased antigenicity. Deletion of the whole C-terminal domain is avoided to protect the secondary structures of the domain that are required for TCS folding. The antigenicity of the C7 variant decreased by 2.7 times in vitro ribosome-inactivating activity, and in vivo cytotoxicity was ten times less than that of the wild type. Therefore, the C7 variant is a potent RIP and cytotoxin that is effective in the nanomolar range [14, 26] .
Further investigations showed two antigenic sites of TCS, YFF81-83 and KR173-174, that are mutated by site-directed mutagenesis. PEGylation with PEG-maleimide results in the production of three mutants. Ribosome inactivation activity of these mutants was similar to nTCS. This activity is reduced seven to ten times after conjugation to PEG-maleimide and is the result of steric hindrance of PEG on interaction between the TCS and the ribosome. Immunogenicity and toxicity decreases after site-directed mutagenesis and PEGylation, suggesting that two selected sites are located at or near the antigenic determinants of TCS. The nonspecific binding and uptake of TCS by normal cells might also be suppressed by PEGylation, which shields ionic strengths [61] .
Conclusions and prospects
RIPs have been used for the preparation of immunotoxins (via antibody conjugates), thus offering great potential as therapeutic agents. MAP30 has provided insight into biomedical applications of RIPs as antitumor and antiviral agents, specifically against HIV, showing great promise as an alternative therapy for AIDS. Furthermore, studies characterizing the mechanism of cell entry and intracellular trafficking of Type II RIPs have also provided insight into the therapeutic use of RIPs, including potential therapeutic roles of a-MMCs, b-MMCs and MAP30 in targeting internalized HIV in T-cells of patients with HIV. All type I RIPs investigated to date show antiviral activity against plant, fungal and animal viruses. Investigation of their interaction and transport into infected cells is required to understand their toxic effect and to find cures for the diseases caused by such viruses.
Although reported to be independent of the inhibition of cellular DNA and protein synthesis, the mechanisms through which RIPs exert their antiviral activity warrants further investigation. In such a situation, it is important to investigate the potential of RIPs in therapeutic intervention as HIV is a complex virus and elongation by inactivating the ribosome [24] . All plant RIPs share the common property of inactivating ribosomes and inhibiting protein synthesis. RIPs damage ribosomes in an irreversible manner by removing adenine residue from 28S rRNA by N-glycosidase activity (Fig. 1) . The removal of one adenine base renders the 60S subunit of eukaryotic ribosomes unable to bind the elongation factor 2 (EF-2), with consequent arrest of protein synthesis [23] .
RIPs are classified into three types: type I composed of a single polypeptide chain; type II, a heterodimer consisting of an A-chain, functionally equivalent to a type I, which is attached to a sugar-binding B chain;
Type III, a single chain containing an extended carboxyl-terminal domain with unknown function [20, 25] . [20] .
Ribosome inactivating proteins (RIPs) exhibit important antiviral properties against viruses by virtue of their broad-spectrum antiviral activity. RIPs inhibit replication of RNA as well as DNA viruses. Antiviral research has been focused on RIPs that interfere with various parts of the viral life cycle and most of the recent work has been focused on the ability of RIPs to act against Human immunodeficiency virus (HIV) [11, 21] .
Trichosanthin (Trichosanthes kirilowii), PAP (Pokeweed americana) and MAP30 (Momordica charantia)
have been reported to inhibit HIV-1 replication in vitro [1] . Trichosanthes was the first RIP to be tested in phase I clinical trials during a time when AZT (zidovudine) was the only drug approved to treat HIV infection [4] . However, the exact mechanism of antiviral activity is still not clear. It was initially thought it involved inactivation of the host cell ribosomes, leading to inhibition of viral protein translation and host cell death. However, with the help of recombinant techniques, mutated RIPs were produced and it was possible to ascertain that the ribosome-inactivating and antiviral activities could be separated [24] . The aim of this review is to describe several plant RIPs and discuss recent progress in establishing the anti-viral activities of these proteins.
RIPs have antiviral activity against plant, fungal and animal viruses. The antiviral activity against animal virus has led to numerous studies on the effect of RIPs. Investigations on RIP were started with the hope that these could be used for AIDS therapy [12, 13] . Important advances were made in the field of RIPs [18] .
HUMAN IMMUNODEFICIENCY VIRUS
Trichosanthin (TCS)
Trichosanthin is a type I RIP extracted from the root tuber of Trichosanthes kirilowii. TCS possess a wide spectrum of biological and pharmacological properties and preferentially inhibited replication of human immunodeficiency virus type I (HIV-1) in both acutely infected T-lymphoblastoid cells and chronically infected macrophages in vitro [16] . Three TCS mutants, (natural TCS) anti-HIV activity is related to its ribosome inactivating activity. HIV replication inhibition was partly due to inhibition of cell proliferation by TCS and its mutants [30] . TCS prevented HIV-1 DNA integration in a dose-dependent manner in cell culture, but did not interfere in viral entry and reverse transcription, but also failed to induce cytotoxicity. HIV-1 integrase can integrate HIV-1 long terminal repeats into cellular chromosome. TCS can efficiently bind and depurinate HIV-1 DNA integration. TCS specifically binds and depurinate HIV-1 long terminal repeats, which is the substrate for HIV-1 integrase and may be responsible for the inhibitory activity on HIV-1 integration [32] . [33] .
TCS
Pokeweed antiviral protein
Pokeweed antiviral protein (PAP) is a ribosome inactivating protein isolated from the leaves of Phytolacca americana and has a unique ability to depurinate HIV-1 RNA. The anti-HIV activity of PAP was attributed to its ability to inhibit viral protein synthesis and depurinate HIV-1 RNA [22] . The antiviral activity of PAP is highly cell selective and greatly enhanced by conjugation to antibodies specific for cell-surface receptors that are capable of being internalized upon ligand occupation [31] .
Immunoconjugates TXU (anti CD7)-PAP and B53 (anti-CD4)-PAP remained healthy and no unusual response or signs of ill health were observed [28] . [5] .
Momordica antiviral protein (MAP30)
MAP30 is a momordica antiviral protein isolated infected human T-cell line cells [14] .
Recombinant MAP30 exhibited similar anti-HIV ativity as observed by nMAP30 (natural MAP30).
Both rec-MAP30 and nMAP30 showed dose dependent inhibition of HIV-1 replication. The ID 50 of both nMAP30 and rec-MAP30 were nearly identical at between 0.2nM and 0.3nM for syncytium formation, p24 inhibition and RT inactivation. Rec-MAP30 was also non toxic to uninfected H9 cells and had no effect on cellular DNA and protein synthesis [12] . Inhibition was also studied by using oligonucleotide substrates with sequence corresponding to U5 regions of HIV LTR [13] .
The proteolytic fragments of MAP30 found to be biologically active. During protease digestion, the central fragments of the MAP30 were protected from proteases and the N-and C-termini were more susceptible to cleavage. Three major proteolysis fragments were generated and two largest fragments expression. These proteolytic fragments were neither inhibitory to cell-free translation nor cytotoxic unlike the full length MAP30. The N-and C-termini of MAP30 were not necessary for anti-HIV activity but were required for ribosome inactivation. The antiviral activity of MAP30 is independent of ribosomal inactivation activity [8] .
Recently, a novel ribosome-inactivating protein (RIP), balsamin was purified from the seeds of Balsam apple, Momordica balsamina. It has a molecular weight of 28 kDa by SDS-PAGE analysis.
Balsamin inhibits protein synthesis in a rabbit reticulocyte lysate-based cell free translation assay with an IC50 of 90.6 ng/mL [11, 21] . The anti-viral activity against HIV of the purified protein is under progress.
Hepatitis B virus (HBV)
Hepatitis B virus is a major agent for liver diseases in Asian countries. It also plays important roles in the development of liver diseases other than HBV. Also, a significant proportion of HIV-infected patients are coinfected with hepatitis B virus (HBV) and these patients are at risk of developing HBV diseaseassociated outcomes, such as cirrhosis, hepatocellular carcinoma and eventually death [2] . MAP30 from time-dependently (p<0.001) [6] .
PAP from Pokeweed americana also inhibited HBV replication in vitro. A eukaryotic expression plasmid respectively after transfection of 1 μg and 2.0 μg plasmid pXF3H-PAP into HepG2 cells [7] .
Herpes simplex virus (HSV)
Herpes simplex virus is a large double stranded linear DNA encased with an icosahedral protein cage.
HSV-1 is an enveloped DNA virus and is the causative agent of several types of primary and recurrent diseases including herpes labialis, gingivostomatitis, keratoconjunctivities and encephalitis. HSV-2 is the major cause of genital herpes; 78-97 percent of HSV-2 infections are asymptomatic. Genital herpes usually spreads through patients with asymptomatic or subclinical infections [17] MAP30 was effective against HSV-1, HSV-2 as well as an HSV specific nucleoside analog cyclovir (ACV)-resistant strain. In HIV patients, HSV infections are much more severe, frequent and life-threatening. In HIV patients, acyclovir (ACV, a HSV specific nucleoside analog) is used to treat HSV infections but they become resistant to ACV due to alterations in the viral DNA polymerase or mutation of the viral enzyme thymidine kinase [18] . antiherpetic activity against ACV-resistant strains was two to three logs more potent than that of ACV [3] .
Trichosanthin, a type I ribosome inactivating replication was due to increased apoptosis in the HSV-1 infected cells [9] . [26] .
Human T-cell leukemia virus
There is no effective antiretroviral treatment to restrict the development of disease associated with HTLV-I.
PAP efficiently inhibited HTLV-I gene expression at both translational and transcriptional levels and efficiently diminished virus production due to suppression of HTLV-I gene expression at both translational and transcriptional level [15] .
Phase I/II clinical trials using RIPs
Trichosanthin, purified from These side-effects were likely not related to trichosanthin because one patient who self-administered 104 mg/kg of trichosanthin had no such side effects [4] .
GLQ223 is a highly purified formuation of and joint aches and an increase in creatinine kinase levels. Anti-GLQ223 antibody levels were detected in most patients and greatest increase in β2-microglobulin and CD4 + T-cell levels were observed after the third and fourth doses of GLQ223. The majority of side-effects were classified as mild, reversed with simple treatments and repeated dosing with GLQ223 was safe [10] .
TXU (anti-CD7)-PAP showed favorable pharmaco- NK cell numbers and reduced viral burden [27] . 
CONCLUSION
